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ABSTRACT OF THE DISSERTATION 
 
p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers 
Rb-Hdm2 interaction and apoptosis 
 
by  
Rachel Baker Delston 
Doctor of Philosophy in Biology and Biomedical Sciences (Molecular and Cellular Biology)  
Washington University in St. Louis, 2009  
Professor J. William Harbour, Chair 
 
 
The retinoblastoma protein (Rb) inhibits both cell division and apoptosis, but the mechanism by 
which Rb alternatively regulates these divergent outcomes remains poorly understood.  Cyclin 
dependent kinases (Cdks) promote cell division by phosphorylating and reversibly inactivating Rb 
by a hierarchical series of phosphorylation events and sequential conformational changes.  The 
stress-regulated mitogen activated protein kinase (MAPK) p38 also phosphorylates Rb, but it 
does so in a cell cycle-independent manner that is associated with apoptosis rather than with cell 
division.   Here, we show that p38 phosphorylates Rb by a novel mechanism that is distinct from 
that of Cdks.  p38 bypasses the cell cycle-associated hierarchical phosphorylation and directly 
phosphorylates Rb on Ser567, which is not phosphorylated during the normal cell cycle.  
Phosphorylation by p38, but not Cdks, triggers an interaction between Rb and the human 
homologue of murine double minute 2 (Hdm2), leading to degradation of Rb, release of E2F1 and 
cell death.   These findings provide a mechanistic explanation for how Rb regulates cell division 
and apoptosis through different kinases, and reveal how Hdm2 may functionally link the tumor 
suppressors Rb and p53. 
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Chapter 1 
 
Introduction 
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1.1 Introduction to the dissertation 
This thesis addresses a central question in cell signaling field—how do proteins control the fate of 
the cell?  More specifically, we investigated how the retinoblastoma protein (Rb) regulates two 
central cellular processes—cell division and cell death.  This work sheds light on both basic 
research on how cells choose to divide versus die and also on translational research as the Rb 
pathway is disrupted in virtually all cancers.  Understanding the intricacies of Rb signaling could 
lead to advances in treating cancer.  Using melanoma cells as a model system we found that 
p38, a MAPK member, phosphorylates Rb on residue Ser567 during genotoxic stress.  In this 
chapter, the major proteins and cellular processes discussed in the dissertation are introduced. 
 
1.2 The retinoblastoma protein and the pocket protein family   
This dissertation centers around the tumor suppressor Rb.  Located on chromosome 13q14, the 
RB gene encodes the ubiquitously expressed 110 kDa Rb protein.  A nuclear phosphoprotein that 
regulates the G1/S cell cycle checkpoint, Rb also plays a critical role in differentiation, 
chromosomal stability, and cell survival (Fung et al., 1987; Halaban, 2005; Harbour and Dean, 
2000b; Knudsen et al., 1999; Lee et al., 1987; Zhang et al., 2000; Zheng and Lee, 2002).  Rb has 
16 potential Cdk serine/threonine-proline phosphoacceptor sites located throughout the protein 
(Figure 1.1).  Rb consists of an N-terminus, a pocket domain, and a C-terminus.  The N-terminus 
is not required for tumor suppressor ability and for many years was thought to have no function.  
More recently, it has been shown to be similar in structure to the pocket domain and  to be 
capable of binding the pocket domain (Hassler et al., 2007).  The pocket domain, so called 
because it forms a pocket-like structure, consists of an A box, a spacer, and a B box.  The B box 
contains a leucine-x-cysteine-x-glutamate  (LxCxE) consensus sequence that allows for binding 
to chromatin remodeling enzymes and viral oncoproteins such as Adenovirus E1A, SV40 Large T 
antigen and Papillomavirus E7 (Chow et al., 1996; DeCaprio, 2009; Dyson et al., 1989; Kaelin et 
al., 1992; Weintraub et al., 1992).  The pocket domain is essential for tumor suppressor ability 
and is highly conserved across species.  The A and B boxes are similar in structure to cyclins and 
may have originated from duplication of cyclins (Claudio et al., 2002).  The E2F transcription 
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factor (E2F) binding site spans the B box and the C-terminus and is distinct from the LxCxE site 
allowing Rb to simultaneously bind both E2Fs and chromatin remodeling enzymes, creating a 
repressor complex (Harbour and Dean, 2000a).  The C-terminus of Rb is progressively 
phosphorylated during the cell cycle and also binds several proteins including c-Abl (a pro-
apoptotic tyrosine kinase proto-oncoprotein) and the human homologue of murine double minute 
2 (Hdm2) (Borges et al., 2007; DeCaprio et al., 1992; Uchida et al., 2005). 
 
Rb is a member of the pocket protein family which also includes p107 (Retinoblastoma-like 
protein 1) and p130 (Retinoblastoma-like protein 2).  As the name suggests, the family shares 
homology in the pocket domain.  Like Rb, p107 and p130 halt the cell cycle by recruiting 
chromatin remodeling complexes and repressing E2Fs, are phosphorylated by cyclin-Cdk  
complexes, and lose tumor suppressor ability when bound by LxCxE motif containing DNA tumor 
viruses (DeCaprio, 2009; Sun et al., 2007).  The pocket protein family members have varying 
expression levels in the cell.  Rb remains constant throughout the cell cycle, p130 is high in G0 
and differentiated cells and low in proliferating cells, while p107 has just the opposite expression 
pattern (Genovese et al., 2006).  Interestingly, recent work revealed that Rb, p107, and p130 can 
all bind the RB promoter and regulate Rb transcription (Burkhart et al., 2010).  While 
compensation for Rb does not appear to occur in humans, p107 can compensate for loss of Rb in 
the mouse.  Rb related proteins with conserved pocket domains have been found in a variety of 
species ranging from Drosophila and C. elegans to plants such as maize and Arabidopsis.  The 
alga Chlamydomonas has a protein with a region homologous to the pocket, including the LxCxE 
domain and the spacer, however the protein does not play a role in G1 arrest (Claudio et al., 
2002; Genovese et al., 2006).  And while they have no sequence similarities, Rb does have a 
functional homolog in yeast, Whi5 (Cooper, 2006). This dissertation focuses on Rb, as it is the 
primary family member disrupted in cancer (Ewen et al., 1991; Yeung et al., 1993). 
 
1.3 Rb is a tumor suppressor  
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Cancer is a term for many diseases which can be grouped together as all having uncontrolled 
growth of damaged cells.  Cancer is second most common cause of death in the United States 
(ACS, 2010).  There were over 1.5 million new cancer cases and over half a million people are 
expected to die of cancer in the Unites States in 2010 (ACS, 2010).  Many factors contribute to 
cancer such as genetic predisposition, aging, physical carcinogens (such as ultraviolet and 
ionizing radiation), chemical carcinogens (such as tobacco smoke and asbestos) and infections 
(viruses and bacteria).  During carcinogenesis a cell with damaged DNA replicates out of control 
due to inherited or progressive genetic changes involving overexpression of oncogenes and 
inactivation of tumor suppressor genes.  Hanahan and Weinberg have suggested 6 hallmarks of 
cancer: self-sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) signals, 
evasion of programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 2000).  
One such type of cancer is retinoblastoma, the most common form of eye cancer in children.  
One patient per 20,000 live births is affected and there are about 300 cases of retinoblastomas a 
year in the United States (ACS, 2010; Harbour, 2006).  The disease typically affects children 
under two years of age and when treated properly the survival rate is greater than 90%.  One way 
in which retinoblastoma is diagnosed is through a child‘s eye appearing white in a photograph 
due to the tumor preventing the light from reaching the retina (Figure 1.2).  Treatment options 
include enucleation (removal of the eye), plaque radiation, laser therapy, and chemotherapy.   
When left untreated retinoblastoma can metastasize to the lungs, bone, brain, and other sites  
(Harbour et al., 1994). 
 
The study of retinoblastoma the disease and the Rb protein have led to major advances in the 
understanding of cancer.  In 1971 Knudson proposed the two hit hypothesis, that cancer is 
caused by two mutational events, based on retinoblastoma cases, creating a paradigm shift in the 
field (Knudson, 1971).  He hypothesized that either a germline mutation was present at birth and 
a second somatic mutation occurs (hereditary) or two somatic cell mutations occur (non-
hereditary).  Hereditary retinoblastoma makes up 40% of cases and is usually diagnosed 
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between six and twelve months of age.  Tumors are most often present in both eyes, but primary 
tumors can occur in other locations such as the skin and bone.  In non-hereditary retinoblastoma, 
which make up 60% of cases, the tumor is unilateral and there is no risk of tumor formation in the 
other eye.  Non-hereditary retinoblastoma is usually diagnosed later, between one and two years 
of age.   
 
Following up on Knudson‘s finding, Friend and colleagues cloned RB in 1986 and classified it as 
the first tumor suppressor (Friend et al., 1986).  Further work revealed that the RB gene is 
mutated in additional cancers such as small cell lung cancer and osteosarcomas (Harbour, 1998; 
Harbour et al., 1988; Wadayama et al., 1994).  In virtually all other types of tumors the Rb protein 
is functionally inactivated through hyperphosphorylation, by over-expression of cyclin D 
(regulatory subunit) which activates its catalytic counterpart cyclin dependent kinase (Cdk) 4/6, or 
through inactivation of the Cdk4/6 inhibitor p16
Ink4a
 (Okamoto et al., 1994; Rogoff and Kowalik, 
2004; Sherr, 1996).   
 
1.4 Mouse models of Rb   
There is 91% amino acid identity and 87% nucleotide identity between human and mouse Rb, 
thereby making the mouse an excellent system in which to study Rb.  The first knockout mouse of 
a tumor suppressor, the RB knockout mouse, was created by Tyler Jacks in 1992 (Clarke et al., 
1992; Jacks et al., 1992; Lee et al., 1992).  Deleting RB is embryonic lethal between days E12-
15.  The mice have defects in neurogenesis and erythropoiesis, and massive apoptosis and 
excessive proliferation occurs.  Chimeric mice composed of Rb-deficient and wildtype cells are 
viable and rapidly develop pituitary tumors and thyroid adenomas but do not develop 
retinoblastomas (Maandag et al., 1994; Williams et al., 1994).  Heterozygous Rb
+/-
 mutant mice 
primarily develop tumors of the pituitary gland and thyroid hyperplasia, but no retinoblastomas 
develop in these mice (Jacks et al., 1992). In order to create an in vivo model that recapitulates 
human retinoblastoma, p107 or TP53 must be knocked out in addition to RB (Zhang et al., 2004).  
Knocking out E2F partially rescues the RB null phenotype (Tsai et al., 1998).  
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A decade after the first RB knockout mouse was made, Wu et al published a landmark paper 
revealing that a wildtype placenta largely rescues the RB null phenotype (Wu et al., 2003).  Pups 
were able to reach term, although they died shortly after birth.  These studies revealed that many 
of the features of the RB knockout phenotype were due to excessive trophoblast (placenta 
precursor cells) proliferation rather than cell autonomous effects of Rb loss per se.  
 
1.5 Rb arrests cell cycle at the G1 checkpoint through interaction with E2Fs 
The cell cycle, the process in which one cell divides and replicates into two daughter cells, can be 
broken up into several phases (Coller, 2007).  G1 (a gap phase during which the cell grows in size 
and a checkpoint to confirm the cell is free of DNA damage), S (the synthesis phase in which 
DNA replication occurs), and G2 (a second growth and checkpoint gap), all make up the 
Interphase portion of the cell cycle.  The final phase is Mitosis in which the chromosomes divide 
and cytokinesis occurs.  G0 is a resting state in which cells have arrested and exited the cell 
cycle.  Cells can reenter the cell cycle from this quiescent state or can remain in G0 indefinitely as 
is the case for fully differentiated cells.   
 
Rb plays a critical role in the cell by arresting damaged cells at the G1 checkpoint.  The ability of 
Rb to arrest cells in G1 is intricately linked to its ability to regulate E2Fs (Coller, 2007).  The E2F 
family includes E2Fs 1, 2, and 3a, activators which promote transcription of cell cycle promoters 
in late G1 and S phases, and E2Fs 3b, 4, and 5, repressors which abrogate transcription of cell 
cycle promoters during G0 and G1 phases.  E2Fs 6-8 are repressors thought to recruit chromatin 
remodeling complexes to DNA (van den Heuvel and Dyson, 2008).  Rb binds the C-terminal 
activation domain of E2Fs 1-5.  p130 and p107 also bind E2F3b, 4, and 5.  E2Fs 1-6 
heterodimerize with the differentiation-regulated transcription factor-1 polypeptide (DP) family.  
Rb represses transcription by at least two basic mechanisms.  First, Rb binds and blocks the E2F 
transactivation domain (Flemington et al., 1993; Helin et al., 1993).  Second, when Rb is brought 
to promoters through interaction with E2Fs, it actively represses transcription.  Rb recruits 
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chromatin remodeling proteins to promoters where they alter local chromatin structure and inhibit 
access of the transcriptional machinery (Frolov and Dyson, 2004; Harbour and Dean, 2000a; 
Weintraub et al., 1992).  Several major classes of chromatin remodeling proteins have been 
shown to interact with Rb, including histone deacetylases (e.g., HDAC1-3) which promote 
nucleosome formation, SWI/SNF ATP-dependent nucleosome assembly proteins (e.g., BRG1 
and BRM), polycomb group proteins (e.g., HPC2 and Ring1), DNA methyl-transferases (e.g., 
DNMT1), and histone methyltransferases (e.g. SUV39h) (Brehm et al., 1998; Dahiya et al., 2001; 
Dunaief et al., 1994; Eden et al., 1998; Frolov and Dyson, 2004; Lai et al., 1999; Lu and Horvitz, 
1998; Luo et al., 1998; Magnaghi et al., 1998; Nielsen et al., 2001; Panteleeva et al., 2004; 
Robertson et al., 2000; Schumacher and Magnuson, 1997; Trouche et al., 1997; Vandel et al., 
2001).   
 
1.6 Phosphorylation of Rb allows for cell cycle progression 
Rb is progressively phosphorylated throughout the cell cycle (DeCaprio et al., 1992).  
Phosphorylation of Rb is catalyzed by cyclin D-Cdk4 in early G1 (Kato et al., 1993), then by cyclin 
E-Cdk2 late in G1, and later by cyclin A-Cdk2 in S phase (Sherr, 1996).  These multiple 
phosphorylation events are necessary to inactivate Rb and allow for cell cycle progression 
(Lundberg and Weinberg, 1998).  The progressive phosphorylation of Rb is hierarchical as the C-
terminal sites are more readily phosphorylated than the pocket sites (Ma et al., 2003).  
Mechanistically, this can be understood as a stepwise series of increasingly energetically 
unfavorable phosphorylation events in which phosphorylation of an initial set of sites triggers 
intramolecular interactions that enable phosphorylation of the next set of sites (Figure 1.3) 
(Delston and Harbour, 2006; Harbour et al., 1999; Rubin et al., 2005).  Similar sequential 
phosphorylation mechanisms have been shown for other proteins such as c-Fos (Mackeigan et 
al., 2005).  Phosphorylation of Rb at sites in the C-terminus triggers an intramolecular 
conformational change in which the negatively charged C-terminus interacts with a positively 
charged lysine patch in the B box of the pocket domain (Harbour et al., 1999).  Subsequent 
crystallographic studies confirmed this interaction between the C-terminus and pocket domain 
  
8 
 
(Lee et al., 2002; Rubin et al., 2005).  The intramolecular interaction displaces LxCxE proteins 
such as HDACs from Rb, and this inactivation is sufficient to abrogate the ability of Rb to block 
the G1-to-S transition (Zhang et al., 2000).  
 
1.7 p53 is a tumor suppressor  
There is significant crosstalk between the Rb and p53 pathways and therefore it is difficult to 
study one pathway without considering the other.  E2F1 concomitantly transactivates ARF and 
ataxia telangiectasia mutated (ATM) which stabilize and activate p53 respectively (Berkovich and 
Ginsberg, 2003).  In the following chapters, we investigate the role of p53 in genotoxic stress-
induced apoptosis in melanoma cells. 
 
p53 is the 393 amino acid product of the TP53 gene located on 17p13.1.  While it migrates at 53 
kDa as its name suggests, its actual mass is 43.7 kDa.  p53 is a transcription factor that forms 
homotetramers .  In 1991, experiments on myeloid leukaemic cells revealed that p53 acts as a 
tumor suppressor as addition of p53 caused these cancerous cells to die (Yonish-Rouach et al., 
1991).  p53 acts as a tumor suppressor  by promoting apoptosis, senescence, or cell cycle arrest 
.  p53 is mutated in over half of cancers and loss of TP53 in mice promotes tumors (Donehower 
et al., 1992; Hollstein et al., 1991; Jacks et al., 1994; Lowe et al., 1994; Yonish-Rouach et al., 
1991).  It is part of a family which includes p63 and p73 and while all three members can induce 
apoptosis, only p53 is commonly mutated in cancer (Dobbelstein and Roth, 1998; Marin et al., 
1998).  Interestingly, an ancestor of this family is present in organisms as evolutionally ancient as 
the sea anemone, where the protein promotes apoptosis in response to DNA damage (Belyi et al. 
2010).   
 
p53 is activated in response to a variety of stress signals such as oncogenic stimuli, hypoxia, and 
DNA damage (Levine, 1997).  p53 is also activated and promotes apoptosis in response to 
disruption of the Rb pathway.  Therefore, loss of Rb creates genomic instability and selective 
pressure for tumor cells to mutate p53 (Sherr, 2004).  Rb plays a necessary role in the ability of 
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p53 to promote cell cycle arrest in response to DNA damage.  Rb null/p53 wildtype cells undergo 
apoptosis, not arrest, in response to DNA damage.  On the contrary, Rb can modulate the DNA 
damage response without the presence of p53 (Harrington et al., 1998; McClendon et al., 2010).   
 
1.8 The INK4A/ARF locus   
The INK4A/ARF locus is one of the most commonly targeted loci in cancers. Tumor cells delete 
the locus or methylate CpG-rich islands in the promoter regions, which represses transcription.  
Loss of INK4A and ARF disrupts the two major tumor suppressor pathways, Rb and p53, 
respectively.  The INK4A/ARF locus encodes for two tumor suppressors in an unusually efficient 
use of transcript.  Unique first exons are spliced into common exons 2 and 3 producing two 
unique proteins; the aptly named Inhibitor of Cdk4 (p16
 Ink4a
) and Alternate Reading Frame 
(p14
ARF
).  p16
Ink4a
 leads to dephosphorylation and activation of Rb and cell cycle arrest.   p14
ARF
 
resides in the nucleolus, a non-membrane-bound organelle in the nucleus where ribosomal 
biogenesis occurs, and is maintained at low levels in normal cells.  Loss of ARF and INK4A in 
mice promotes tumorigenesis (Matheu et al., 2004; Sharpless et al., 2004).   
 
DNA damage, Ras, Myc, or other pro-oncogenic signals leads to increased levels of p14
ARF
.  p53, 
which is normally kept at low levels by Hdm2-mediate degradation, is stabilized by p14
ARF
.  
p14
ARF
 stabilizes p53 by sequestering Hdm2 in the nucleolus so that it is unable to degrade p53.  
(Weber et al., 2000; Weber et al., 1999). In addition to Hdm2, p14
ARF
 binds other proteins such as 
E2F1, Myc, and nucleophosmin (NPM), which is involved in ribosome biogenesis and in 
stabilization of p14
ARF
 (Brady et al., 2004; Yu et al., 2006).   
 
1.9 Rb and DNA damage  
Genotoxic stress or DNA damage is an insult to the cell that damages DNA through double strand 
breaks, single strand breaks, thymine dimers, or other abnormal changes to base pairs of DNA.  
Genotoxic stress is caused by a variety of methods such as etoposide, gamma irradiation, UV 
exposure, and replication errors.  In our experiments, we employed etoposide, a topoisomerase II 
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inhibitor used in chemotherapy, which induces double strand breaks in a similar manner to 
irradiation (Sun et al., 2005).  Double strand breaks activate the DNA damage response pathway 
which is mediated by ATM and goes on to activate many downstream targets.  One such target is 
nibrin, a component of the MRE11/RAD50 double-strand break repair complex.   Nibrin is 
involved in non-homologous end joining and preventing S phase progression in cells with double 
stranded breaks (Wilda et al., 2000).  p53, Rb, and E2F1 are also activated by ATM in order to 
promote cell cycle arrest, DNA repair, or death depending on the level of stress (Kastan et al., 
1991; Rogoff and Kowalik, 2004; Sherr, 2004).  
 
DNA damage promotes Rb-mediated cell cycle arrest through activation of cyclin-dependent 
kinase inhibitors (CKIs).  CKIs prevent formation of cyclin-Cdks complexes rendering them unable 
to phosphorylate Rb.  p16
 Ink4a
 inhibits cyclin D1 from activating Cdk4 and Cdk6.  p21
Cip1
 and 
p27
Kip1
 inhibit cyclin E from activating Cdk2.  In fact CKIs are currently being investigated for use 
in clinics to counteract the overexpression of cyclin-Cdks which occurs in many cancers (Galons 
et al., ; Malumbres et al., 2008; Sutherland and Musgrove, 2009).   
 
E2F1 is activated during DNA damage by both acetylation and phosphorylation.  Rb has a 
separate binding site contained in the C-terminus, rather than spanning the pocket domain and C-
terminus, that binds E2F1, but not the other E2F family members.  DNA damage activates 
PCAF/p300 which acetylates E2F1, resulting in loss of binding between E2F1 and this secondary 
C-terminal site on Rb, but leaving the other E2Fs unaffected.  E2F1 is now released to 
transactivate pro-apoptotic target genes (Dick and Dyson, 2003; Engelmann and Putzer).  E2F1 
is phosphorylated on Ser31 and Ser364 in response to stress by ATM/ATR and Chk1/2.  E2F1 
also transcriptionally activates ATM/ATR and Chk1/2 creating a positive-feedback loop 
(Berkovich and Ginsberg, 2003; Lin et al., 2001; Powers et al., 2004; Stevens et al., 2003; Urist et 
al., 2004). 
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p53 levels are kept low by Hdm2-mediated degradation.  In response to DNA damage, E2F1 
transactivates p14
ARF
 which inhibits Hdm2 from degrading p53.  In parallel, ATM phosphorylates 
p53 on Ser15, stabilizing p53, which can then arrest cells through Rb by activating p21
Cip1 
or 
promote apoptosis by acting as a transcription factor depending on the severity of the DNA 
damage signal (Sherr and Weber, 2000).  Like E2F1, p53 is also phosphorylated by ATM and 
CHK1/2 and acetylated by PCAF/p300 (Polager and Ginsberg, 2009).  These events promote 
p53-mediated apoptosis.  
 
Cells must repair DNA damage before the cell replicates in order to maintain genomic stability.  
Rb plays a key role in the maintenance of the integrity of the genome. Loss of Rb leads to both 
aneuploidy and genomic instability (Knudsen and Wang, 2010 ; Zheng and Lee, 2002; Zhou and 
Elledge, 2000). The importance of Rb and E2F for the DNA damage response is well conserved.  
RBF and dE2F play an important role in responding to DNA damage in Drosophila (Du et al., 
1996; Moon et al., 2008). 
 
1.10 Rb is ubiquitinated by Hdm2 and degraded by the proteosome  
The proteosome is the recycling center of the cell.  Proteins are recognized by the 19S cap of the 
proteosome and translocated into the central pore of the 20S core where proteins are degraded 
into short peptides.  The peptides are then used as building blocks for nascent proteins.  A chain 
of ubiquitin groups attached to a lysine on the target protein marks the protein for the 
proteosome.  A ubiquitin group is transferred from an E1 ubiquitin-activating enzyme to an E2 
ubiquitin-conjugating enzyme, and finally to an E3 ubiquitin ligase in order to covalently link the 
ubiquitin group to the target protein in an ATP-dependent reaction.   
 
Hdm2   is an E3 ubiquitin ligase for Rb, as well as for p53 and itself.  The RING finger domain of 
Hdm2 possess ubiquitination activity (Fang et al., 2000; Sdek et al., 2004; Uchida et al., 2005; 
Xiao et al., 1995).  Phosphorylation of Hdm2 at serine 269 impairs its interaction with the Rb 
protein.  Hdm2 binds the Rb C-terminus on 792-928, leading to an increase in E2F activity.  The 
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central acidic domain of Hdm2 (amino acids 254-264) is critical for the Hdm2-Rb interaction 
(Sdek et al., 2005).  p14
ARF
 is an Hdm2 agonist which is well known to inhibit Hdm2 ubiquitination 
of p53 by sequestering Hdm2 to the nucleus (Weber et al., 2005; Weber et al., 1999), but more 
recently has been shown to inhibit Hdm2-mediated ubiquitination of Rb (Uchida et al., 2005).  The 
mechanism of Hdm2 ubiquitination of Rb is discussed in Chapter 3.   
 
1.11 The Apoptotic response  
Apoptosis, or programmed cell death, involves condensation of chromatin, fragmentation of DNA, 
blebbing of membranes, and shrinking and rounding of cells (Kerr et al., 1972).  Apoptosis takes 
its name from Greek; apo meaning from and ptosis meaning falling, suggesting leaves falling 
from trees.  Apoptosis is initiated by extracellular signals such as Fas and TNFR1 death receptors 
(extrinsic pathway) or intracellular signals such as release of cytochrome c from the mitochondria 
(intrinsic pathway).  Commitment to the apoptotic response is determined by the Bcl2 family 
which consists of anti-apoptotic members such as Bcl2 and BclxL and pro-apoptotic members 
such as Bad, Bax, and Bid (Gross et al., 1999).  Cysteine proteases called caspases execute the 
apoptotic response. Inactive zymogens (pro-caspases) are cleaved and activated during the 
apoptotic response and go on to cleave target proteins.  Initiator caspases (2, 8, 9, and 10) 
cleave and activate effector caspases (3,6, and 7) which promote transcription of pro-apoptotic 
genes.  The extrinsic pathway signals through caspase 8 and the intrinsic through caspase 9 
which both converge on caspase 3 to meditate the downstream response by cleaving cellular 
proteins such as poly(ADP-ribose) polymerase (PARP) which promotes DNA repair by activating 
the ATM pathway (Ranger et al., 2001). 
 
1.12 p38 is a member of the MAPK family  
p38 is a member of the mitogen-activated protein kinase (MAPK) family.  The mechanism of p38-
mediated phosphorylation of Rb will be discussed in the following chapters.  MAPKs are a family 
of proteins conserved from yeast to humans that were discovered in the 1980s (Roux and Blenis, 
2004; Sturgill and Ray, 1986; Widmann et al., 1999).  There are four major arms of the MAPK 
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family; ERK1/2, ERK5/BMK1, SAPK/JNK, and p38 (Figure 1.4).  They are activated by dual 
phosphorylation on Thr-X-Tyr motifs.  MAPKs utilize a signaling cascade in which a biological 
response is elicited by a MAPK which is activated by a MAPK kinase (MAPKK), which in turn is 
activated by a MAPK kinase kinase (MAPKKK), which is activated by a variety of stimuli (Raman 
et al., 2007).  The signaling cascade allows for many levels of regulation and amplification.   
 
A variety of stimuli such as osmotic shock, inflammatory cytokines, lipopolysaccharides (LPS), 
UV light and growth factors, and Rho GTPases activate the p38 arm of the MAPK pathway.  
MAPKKKs; mixed lineage kinase 3 (MLK3), TGF-beta activated kinase 1 (TAK), delta-like-1 
(DLK1), MEKK4, or Apoptosis Signal-Regulating Kinase 1 (ASK1) activates the MAPKKs; MKK3, 
MKK4 or MKK6, which activates the MAPK p38.  MKK3 and MKK6 activate p38 exclusively while 
MKK4 also activates SAPK/JNK (Cuenda, 2000; Enslen et al., 1998).  All three MKKs activate all 
4 isoforms of p38 except for MKK3 which does not activate p38β.  p38 activates many 
downstream targets to promote apoptosis (if there are high levels of p38) or arrest (if there are 
lower levels of p38) such as MEF2C, ATF1, CHOP, ELK-1, p53, p73, and MAPK2 (which 
activates Hdm2). 
p38 was discovered in 1994 as a tyrosine phosphoprotein in extracts of cells treated with
 
inflammatory cytokines.  At the same time it was discovered as a target of a pyridinyl imidazole
 
drug that blocked production of tumor necrosis factor (TNF)
 
and as such was briefly called 
cytokine-suppressive anti-inflammatory drug binding
 
protein or CSBP.  In parallel, it was found in 
a screen as a kinase for the substrate MAPK2 (Han et al., 1994; Lee et al., 1994; Pearson et al., 
2001).  There are four isoforms of p38 which share 60% amino acid sequence homology.  p38α 
and p38β are ubiquitous, p38γ is found in skeletal tissue, and p38δ is expressed in lung, kidney,
 
pancreas, placenta, and testis.  While p38α knockout mice are embryonic lethal, knockouts of the 
other isoforms are viable.  p38 resides in both the cytoplasm and nucleus but does not have a 
nuclear localization signal (Ben-Levy et al., 1998).  Wip1/PPMID is a phosphatase for p38 and is 
a downstream target of p53 and E2F1 (Takekawa et al., 2000).   p38 is overexpressed in many 
cancers (Yu et al., 2007).   
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1.13 Melanoma cells as a model system to study the role of Rb during stress  
In this dissertation, we use melanoma cells as a model system to study the Rb pathway.  
Melanocytes are neural crest derived cells located in the basal layer of the skin, the uvea of the 
eye, the inner ear, the meninges, bones, and in the heart (Bennett, 1993).  Melanocytes are 
spindle-shaped cells that produce the pigment melanin.  Melanoma, the cancer resulting from 
malignant transformation of melanocytes, occurs most often in the cutaneous form, but also can 
occur in the uveal tract of the eye, mucosal tissues, and other sites (Curtin et al., 2005; Harbour, 
2003; Harbour, 2006; Rager et al., 2005; Sirsat, 1952).   
 
Melanoma cells are a useful system to study Rb because they undergo apoptosis under Rb null 
conditions and therefore exemplify the central role of Rb in cell survival (Bennett and Medrano, 
2002; Macleod et al., 1996).  The Dowdy lab demonstrated that ablation of RB in melanocytes by 
cutaneous application of Tat-Cre in LoxP-Rb mice causes selective apoptotic loss of melanocytes 
(Yu et al., 2003).  Acute inactivation of Rb in vivo by conditional mutagenesis in the skin resulted 
in the selective loss of melanocytes and severe depigmentation, indicating that Rb has a cell-
autonomous role in melanocyte survival (Halaban, 1999; Yu et al., 2003).  Indeed, p16
Ink4a
 is 
frequently mutated in familial melanoma, resulting in hyperphosphorylation and inactivation of Rb, 
and individuals with RB gene mutations are at increased risk for melanoma (Begg et al., 2005; 
Halaban, 1999; Luca et al., 1995; Reed et al., 1995; Reymond and Brent, 1995).  Virtually all 
mouse models of melanoma require inhibition of Rb, such as by overexpression of large T 
antigen or by inactivation of p16
Ink4a 
(Castellano and Parmiani, 1999; Yu et al., 2003).  
Additionally, mutations in the RAS-RAF-MAPK pathway, which inhibit Rb through activation of 
cyclin D, are common in melanocytic tumors (Gupta et al., 2005). 
 
Cutaneous melanoma is one of the most common and one of the most deadly types of cancer, 
spreading throughout the lymphatic system.  It is estimated that there will be almost 70,000 new 
cases of melanoma in 2010 and almost 9,000 deaths (ACS, 2010).  One of the most common 
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mutations found in melanoma is in BRAF.  BRAF mutations occur in over 50% of cutaneous  
melanomas with 80% of these mutations being a V599E activating mutation (Davies et al., 2002).  
Raf is a part of the Ras-Raf-Mek-Erk-MAP kinase pathway and mutated BRAF is capable of 
transforming NIH3T3 cells.  Over 25% of cutaneous melanomas harbor mutations in NRAS 
(Saldanha et al., 2006).   
 
Uveal melanoma is the most common cancer of the eye and accounts for about 4% of 
melanomas (Harbour, 2006; Onken et al., 2004).  The iris, ciliary body, and choroid make up the 
uveal tract of the eye (Figure 1.5).  While uveal melanoma is rare, it is highly resistant to radiation 
and chemotherapy and is therefore very difficult to treat.  Additionally, 50% of uveal melanoma 
cases metastasize hematogenously to the liver at which point the median survival is less than 6 
months (Gragoudas et al., 1991).  It is estimated that there will be over 200 deaths due to eye 
cancer and almost 2,500 new cases in 2010 in the United States (ACS, 2010).  The common 
NRAS and BRAF mutations that occur in cutaneous melanoma do not occur in the uveal form of 
the disease (Cruz et al., 2003).  While, no mutations have been found in the RAF/MEK/ERK 
pathway in uveal melanoma, mutations in GNAQ, an activator of this pathway occur in about 50% 
of uveal melanomas (Bauer et al., 2009; Gerami et al., ; Onken et al., 2008; Van Raamsdonk et 
al., 2009; Van Raamsdonk et al., 2004).  Like NRAS and BRAF mutations in cutaneous 
melanoma, GNAQ mutations are most likely an early event as they do not correlate with survival 
(Onken et al., 2008).   
 
1.14 Role of Rb in melanocyte differentiation  
Rb plays a role in differentiation and the tumor suppressor function of Rb appears to be due, at 
least in part, to its ability to induce permanent cell cycle exit in association with senescence and 
differentiation (Dannenberg et al., 2000). The classic example of the role of Rb in differentiation is 
muscle cell differentiation in which Rb cooperates with the muscle-specific transcription factor 
MyoD, to activate genes involved in myocyte differentiation (Gu et al., 1993; Sellers et al., 1998).  
Our lab has shown that melanocyte differentiation is linked to cell cycle exit through activation of 
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Rb by the melanocyte differentiation factor microphthalmia-associated transcription factor (Mitf) 
(Loercher et al., 2005).  Mitf interacts directly with and activates the INK4A gene, causing an 
accumulation of hypophosphorylated Rb and cell cycle arrest.  This Mitf-Ink4a-Rb pathway is 
required for efficient cell cycle exit and melanocyte differentiation in cultured cells and in vivo.  Rb 
may also interact directly with Mitf to co-activate other Cdk inhibitors such as p21
Cip1
, which in 
turn re-enforce hypophosphorylation of Rb (Carreira et al., 2005).  Rb is also important for 
maintenance of the differentiated state.  Our lab found that cells induced to exit the cell cycle and 
to differentiate into melanocytes as a result of enforced Mitf expression occasionally escaped this 
growth inhibition, and these escape clones invariably exhibited methylation and inactivation of the 
INK4A promoter, resulting in hyperphosphorylation of Rb  (Loercher et al., 2005). Thus, inhibition 
of Rb appears to be a key step in melanoma formation by allowing melanocytes to re-enter the 
cell cycle.   
 
1.15 Dissertation goals   
Throughout the years Rb has been portrayed as acting as a simple, binary ―on-off‖ switch 
(Buchkovich et al., 1989; Chen et al., 1989; Coller, 2007; DeCaprio et al., 1989).  When Rb is ―on‖ 
it is active and hypophosphorylated, allowing it to bind and inhibit E2Fs that activate cell cycle 
genes.  Conversely, Rb is inactivated, or ―turned off‖ by hyperphosphorylation during every cell 
cycle, releasing E2Fs to activate cell cycle genes. There are several important weaknesses with 
this model.  The release of E2Fs during cell cycle progression described in this model would also 
promote an apoptotic response, since free E2F promotes apoptosis (Phillips et al., 1997; Young 
and Longmore, 2004b).  Indeed, recent work suggests that E2Fs are not completely released 
from Rb during the cell cycle (Young and Longmore, 2004b).  Phosphorylated Rb and E2F co-IP 
in cycling cells (Ezhevsky et al., 1997).  The Farnham lab has extensively demonstrated, using 
chromatin immunoprecipitation experiments (chIP), that pocket protein-E2F complexes persist at 
many E2F-responsive promoters well beyond the G1/S transition (Ezhevsky et al., 2001; 
Ezhevsky et al., 1997; Wells et al., 2000; Wells et al., 2003).  When Rb is partially phosphorylated 
by Cdk4 to allow cell cycle progression, it retains the ability to bind E2Fs and to repress 
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transcription of some genes (Ezhevsky et al., 2001; Ezhevsky et al., 1997; Wells et al., 2000; 
Wells et al., 2003).   
 
Next, this model does not distinguish between the different phenotypes associated with Rb 
inactivation versus Rb deletion.  There are several lines of evidence revealing that these states 
are functionally different.  The apoptotic response that accompanies deletion or complete 
inactivation of Rb is not seen when Rb is functionally inhibited by phosphorylation (Harbour and 
Dean, 2000b, Shackney, 1999).  For example, the massive apoptosis that occurs in RB-null mice 
does not occur in INK4A-null animals (Serrano et al., 1996), even though this genetic perturbation 
would be expected to maintain Rb in a hyperphosphorylated state.  Similarly, RB-null cancer cells 
(such as retinoblastoma and small cell lung cancer) generally exhibit a high rate of spontaneous 
apoptosis, rapid cell division, and sensitivity to chemotherapy whereas RB-positive cancer cells 
that maintain Rb in a hyperphosphorylated state (such as melanomas) have a much lower rate of 
apoptosis, lower rate of proliferation, and are more resistant to chemotherapy (Shackney and 
Shankey, 1999).  
 
Finally, this model does not explain how Rb regulates both the cell cycle and apoptosis. Indeed, a 
major unsolved question in the field has been how one protein, Rb, could control these opposing 
cell fates.   Experiments by Jean Wang‘s lab suggest that the cell cycle and apoptotic functions of 
Rb may be distinct.  Mice with a mutation in the Rb caspase cleavage site still retain tumor 
suppressor activity (Tan and Wang, 1998).  Furthermore the Wang lab made a mutant in which 
Rb could not longer arrest the cell cycle but could regulate apoptosis (Chau et al., 2006).   
 
In our work, we have addressed this question from a different perspective.  The following 
chapters reveal a novel mechanism  by which the cell cycle and apoptotic functions of Rb are 
differentially regulated (Delston et al., 2010). In Chapter 2, we investigate the p38-Rb signaling 
axis.  Our data reveal that p38 phosphorylates Rb on Ser567, a pocket residue, through a novel 
mechanism leading to apoptosis in a p53- and E2F1-dependent manner.  In Chapter 3, we 
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demonstrate the mechanism behind Rb-mediated apoptosis.  We found that phosphorylation of 
Rb on Ser567 leads to Hdm2-mediated proteosomal degradation of Rb and cell death.  In 
Chapter 4, the dissertation is summarized and future directions are proposed. 
 
  
  
19 
 
1.16 Figures 
 
 
 
 
 
 
 
 
Figure 1.1 Phosphorylation sites on Rb 
There are 16 Serine or Threonine phosphoacceptor sites located throughout the Rb protein: Thr5, 
Ser230, Ser249, Thr252, Thr356, Thr373, Ser567, Ser608, Ser612, Ser780, Ser788, Ser795, 
Ser807, Ser811, Thr821, and Thr826.   
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Figure 1.2 Picture of retinoblastoma tumor 
The white eye seen in this photograph can be a symptom of retinoblastoma.  The tumor blocks 
the light of the flash from reaching the retina.  Image from J. William Harbour. 
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Figure 1.3 A model for sequential phosphorylation of Rb  
Rb phosphorylation occurs in a stepwise and hierarchical fashion.  Hypophosphorylated Rb 
arrests the cell cycle by forming multimeric complexes with E2F and chromatin remodeling 
enzymes (CRE). Partial phosphorylation by cyclin-Cdk complexes results in partial Rb inhibition 
to allow cell cycle progression. During abnormal stress conditions, further sites are 
phosphorylated, such as Ser567, which is efficiently phosphorylated only when Cdk activity is 
abnormally high or when stress kinases are activated. Phosphorylation of this site favors 
apoptosis over cell division by releasing free E2F to activate apoptotic genes. We hypothesize 
that this differential phosphorylation may allow Rb to buffer cells against apoptosis during normal 
cell division but to serve as a death checkpoint that triggers apoptosis in stress conditions.  
Adapted from (Delston and Harbour, 2006). 
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Figure 1.4 The MAPK pathway 
There are four major arms of the MAPK family; ERK1/2, ERK5/BMK1, SAPK/JNK, and p38.  
MAPKs utilize a signaling cascade in which a biological response is elicited by a MAPK which is 
activated by a MAPK kinase (MAPKK), which in turn is activated by a MAPK kinase kinase 
(MAPKKK), which is activated by a variety of stimuli. 
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Figure 1.5 Diagram of the eye 
Image from J. William Harbour.  The iris, choroid, and ciliary body make up the uveal tract of the 
eye.  
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Chapter 2 
 
p38 phosphorylates Rb on Ser567 by a novel mechanism in response to genotoxic stress 
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2.1 Abstract 
 
Rb is a tumor suppressor that regulates cell division, differentiation, and apoptosis.  Rb was first 
identified as regulator of the G1-to-S cell cycle transition; however, it later became evident that Rb 
also plays a role in blocking apoptosis.  While the role of Rb in the cell cycle has been extensively 
studied, the role of Rb in apoptosis and the mechanism by which Rb coordinately regulates these 
two cellular outcomes remains poorly understood.  Cyclin-Cdks phosphorylate Rb on the C-
terminus, allowing for cell cycle progression however, the kinases and phosphorylation sites 
involved in apoptosis are less clear.  In order to investigate the response of Rb to stress, we 
developed a model system in which we treated melanoma cells with a DNA damaging reagent.  
We found that p38 phosphorylates Rb on Ser567 in response to genotoxic stress, by a novel 
mechanism, distinct from Cdk phosphorylation of Rb.  This phosphorylation event results in cell 
death through p53- and E2F1-dependent pathways.  These findings provide a mechanistic 
explanation for how Rb differentially regulates cell division and apoptosis.   
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2.2 Introduction  
 
The current model of Rb function focuses on the role of Rb in the cell cycle and does not address 
the role of Rb in regulating apoptosis.  The existing model posits Rb as an ―on-off‖ switch 
(Buchkovich et al., 1989; Chen et al., 1989; Coller, 2007; DeCaprio et al., 1989).  This model 
asserts that when Rb is ―on‖ it is completely unphosphorylated and bound to E2Fs in order to 
actively halt the cell cycle.  When Rb is ―off‖ it is fully phosphorylated and these events release its 
hold on E2Fs which are now free to transactivate cell cycle genes to promote cell division.  This 
oversimplified model does not take a key piece of information into account; it is known that free 
E2F transactivates pro-apoptotic genes (Young and Longmore, 2004b).  According to this model, 
pro-apoptotic genes would be transcribed with every round of the cell cycle leading to a very 
inefficient means of division.  Additionally, although the current model asserts that phosphorylated 
Rb does not bind E2Fs, there is evidence to the contrary.  Partially phosphorylated forms of Rb 
do indeed bind E2Fs (Ezhevsky et al., 2001; Ezhevsky et al., 1997), and Rb continues to co-
localize with E2Fs at certain promoters in vivo beyond the G1/S transition despite being 
sufficiently phosphorylated to allow for cell cycle progression (Wells et al., 2000; Wells et al., 
2003).   
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To address these unresolved issues we propose an updated model which takes Rb‘s role in 
apoptosis into account.  Instead of only having two states; phosphorylated or unphosphorylated, 
this model envisions Rb as existing with multiple phosphorylation states, that have differing 
abilities to bind E2Fs and other proteins, and to inhibit cell division and apoptosis (Lundberg and 
Weinberg, 1998; Ma et al., 2003).  Work from our lab and others support the idea that different 
phosphorylated forms of Rb allow the cell to differentially control cell cycle genes and apoptotic 
genes, the former being derepressed by partial phosphorylation of Rb and the latter being 
activated by more complete phosphorylation of Rb (Young and Longmore, 2004a; Young et al., 
2003; Zhang et al., 2000).  Taken together, these observations indicate that the decision between 
proliferation and apoptosis is made, at least in part, by the manner in which Rb is phosphorylated.   
 
Previously, Cdks were the only kinases known to phosphorylate and regulate Rb under 
physiologic conditions, but recently other kinases have been shown to phosphorylate Rb.  In 
particular, p38 phosphorylates Rb in response to cellular stress, such as DNA damage and death 
receptor signaling, in multiple cell types, including endothelial cells, cerebellar neurons, Jurkat 
lymphocytic cells, colon cancer cells, and melanoma cells (Dasgupta et al., 2004; Kishore et al., 
2003, Yeste-Velasco, 2009, Nath, 2003; Lee et al., 2003; Pillaire et al., 2000).  Phosphorylation of 
Rb by Cdks, which occurs during normal cell division and in proliferating cancer cells, does not 
lead to apoptosis, at least in part, because Rb is only partially inactivated and can still repress 
pro-apoptotic E2Fs (Wells et al., 2003; Young et al., 2003).  Cdk-mediated phosphorylation is 
reversible, allowing Rb to be dephosphorylated as cells complete the cell cycle.  In contrast, we 
found that p38-mediated phosphorylation leads to degradation of Rb, release of E2Fs, and 
activation of pro-apoptotic genes.   
 
Researchers have focused their attention on the phosphoacceptor sites on the C-terminus of Rb 
which play a role in cell cycle regulation.  However, several lines of evidence point to Ser567 as 
playing an important role in Rb regulation.  Ser567 is the only phosphoacceptor site on the A box 
of the pocket domain of Rb and is located at a critical location at the interface of the A and B 
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boxes and near an E2F binding site (Figure 2.1).  The Ser567-Pro568 phospho-acceptor motif is 
highly conserved across species (Ma et al., 2003).  Ser567 is the only phosphorylation site on Rb 
that is a target of naturally occurring mutations in human retinoblastoma, suggesting that it plays 
a different role than the other 15 phosphorylation sites (Templeton et al., 1991; Yilmaz et al., 
1998).  Strikingly, when Rb is phosphorylated on Ser567 the A and B boxes of the pocket domain 
dissociate (Harbour et al., 1999).   
 
In order to investigate the role of Rb in a setting of genotoxic stress, we established a model 
system of etoposide-treated melanoma cells.  Melanoma cells are an ideal model system as Rb is 
essential for differentiation and survival of melanocytes (Halaban, 1999; Yu et al., 2003).  We 
used melanoma cells called Mel202s which have been extensively characterized.  They are Rb 
and p53 wildtype and have a spindle morphology (Sun et al., 2005 1991).  Mel202s were isolated 
from a uveal melanoma tumor and stop dividing at around 30 passages (Ksander et al., 1991).  
Since there was no satisfactory model in which to study the role of Rb during stress in melanoma 
cells, we decided to use etoposide, a DNA damaging reagent used in cancer treatments. 
Etoposide inhibits topoisomerase II, cuts double stranded DNA, activates the Cdk inhibitor 
p21
Cip1
, and effects cells in a similar manner as ionizing radiation (Sun et al., 2005).  
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Loss of Rb can lead to p53-dependent or p53-independent apoptosis (Jacks et al., 1992; Lee et 
al., 1992; Macleod et al., 1996; Morgenbesser et al., 1994; Wu et al., 2003).  Free E2F can 
stabilize p53 through p14
ARF
 or ATM/CHK1/CHK2 allowing for activation of pro-apoptotic p53 
target genes (Engelmann and Putzer, ; Wu and Levine, 1994).  However, E2Fs can also promote 
p53-independent apoptosis through activation of p73 or BH3-only proteins such as Bid, Bim, and 
Puma (Engelmann and Putzer, ; Hsieh et al., 1997; Phillips et al., 1997).  This finding was 
demonstrated both in vitro in Saos-2 cells which are p53 null and still underwent apoptosis 
(Phillips et al., 1997) and in vivo, as deletion of Rb in p53 null mice led to E2F1-induced apoptosis 
(Macleod et al., 1996).  We investigated the roles of E2F1 and p53 in our system and found that 
apoptosis was E2F1- and p53-dependent.   
 
We sought to determine mechanistically how phosphorylation of Rb by p38 differs from that of 
Cdks and why this results in such a dramatically different physiologic effect (apoptosis versus cell 
division, respectively).  We show that residue Ser567 on Rb is preferentially phosphorylated by 
p38, but not Cdk2, in response to genotoxic stress.  While C-terminal phosphorylation of Rb by 
Cdks results in cell cycle progression, we found that Ser567 phosphorylation of Rb by p38 leads 
to E2F1- and p53- mediated cell death.   
 
  
  
49 
 
 
2.3 Methods 
 
Cell culture  
Mel202 uveal melanoma cells were provided by B. Ksander (Harvard Medical School, Boston, 
MA, USA).  Mel501 cutaneous melanoma cells were provided by L. Cornelius (Washington 
University, St. Louis, MO, USA).  Mel202 and Mel501 cells were cultured in complete RPMI 1640 
medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma 
Aldrich, St. Louis, MO, USA), L-glutamine/antibiotics/anti-mycotics (Mediatech, Manassas, VA, 
USA) for no more than 30 passages.   
 
Primary uveal melanocytes and melanoma cells were collected by J. William Harbour at the time 
of enucleation and maintained by O. Agapova.  Samples were collected in HAM‘S F-12 medium, 
incubated in trypsin and collagenase, and grown at 4% oxygen on collagen-covered tissue culture 
plates in HAM‘s F-12 (Invitrogen) supplemented with 10% BSA (Sigma), SITE supplement 
(Sigma), B27 supplement (Invitrogen), bFGF (PeproTech, Rocky Hill, NJ, USA), L-glutamine 
(Sigma), gentamicin (Sigma) and fungizon.  Primary melanocytes and melanoma cells, Mel202s, 
and Mel501s were grown under 5% carbon dioxide and 4% oxygen.  
 
U2OS osteosarcoma and C33A cervical cancer cells were grown in DMEM (Invitrogen) 
supplemented with 10% fetal bovine serum (Sigma), L-glutamine/antibiotics/anti-mycotics 
(Mediatech) under conditions of 5% carbon dioxide and 21% oxygen. 
 
Inhibitors, constructs, and siRNA 
When indicated, cells were treated with etoposide (Sigma), Cdk2 inhibitor (Roscovitine, Sigma), 
p38 inhibitor (SB 203580 Millipore, Billerica, MA, USA), and Cdk4 inhibitor (EMD, Darmstadt, 
Germany). Transfections of expression plasmids were performed using Effectene or Attractene 
(Qiagen, Germantown, MD, USA).  Transfections of siRNA were performed using HiPerFect 
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(Qiagen).  Validated siRNA against p38α, p38β, and E2F1 (Ambion, Austin, TX, USA), and p53 
(Thermo Fisher Scientific, Waltham, MA, USA), were used.  siRNA against Rb was designed 
using an algorithm previously described (Elbashir et al., 2001).  A fluorescently tagged scrambled 
siRNA was used as a negative control (Allstars Neg siRNA AF488. Qiagen 1027284).  SKTT was 
used as a control in several experiments.  pCMV, pcDNA3, RC-CMV, RC-Cyclin D, RC-Cyclin E, 
p53, CD20, Rb, Rb∆567, Rb∆568, RbΔ780, Rb∆7, and E2F1, expression plasmids were used  
(Harbour et al., 1999; Ma et al., 2003).  RSV2 and RSV2-MKK3 were provided by R. Davis 
(UMass Medical School, Worcester, MA, USA).  The constitutively active p38 expression plasmid 
was provided by D. Engelberg (The Hebrew University of Jerusalem, Jerusalem, Israel) (Askari et 
al., 2009).  Adenovirus expressing GFP (Ad-GFP) was provided by A. Samarel (The 
Cardiovascular Institute, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, 
USA) (Heidkamp et al., 2005).  Adenovirus expressing LacZ (Ad-LacZ) was provided by T. Kuroki 
(Showa University, Hatanodai, Shinagawa-ku, Tokyo, Japan) (Ohba et al., 1998).  Adenovirus 
expressing MKK3 (Ad-MKK3) was provided by Y. Wang (University of California, Los Angeles, 
Los Angeles, CA, USA) (Wang et al., 1998).  Ad-cycD1 was provided by H. Piwnica-Worms 
(Washington University). 
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Antibodies 
Immunoblot analysis, immunoprecipitations  and immunofluorescence staining were performed as 
previously described (Ma et al., 2003).  Bands were quantified using densitometry (Adobe 
Photoshop CS4 extended version 11.0).  Antibodies against total Rb (IF8), E2F1, and total p53 
were used (Santa Cruz Biotechnology, Inc Santa Cruz, CA, USA).  Antibodies against Rb-
phospho-567 were obtained from Santa Cruz and Bethyl Laboratories (Montgomery, TX, USA) as 
previously described (Ma et al, 2003).  Antibody against GST was from Bethyl Laboratories.  
Antibodies against cleaved PARP, phospho-p38, p38 total, cyclin D1, Rb-phospho-807-811, Rb-
phospho-780, Rb-phospho-795, and cleaved caspase 3 were from Cell Signaling Technology 
(Danvers, MA, USA).  Antibody against α-tubulin was from Sigma Aldrich.  α-tubulin was used as 
a loading control in immunoblots.   
 
Cell viability assays  
Cell viability assays were performed with methyltetrazolium sulfate (MTS) using the CellTiter 96 
AQueous kit (Promega, Madison, WI, USA).  Mel202 cells were plated into 96-well culture plates 
at 10
4
 cells per well on the day prior to the assay.  Dilute MTS was applied to each well and 
allowed to incubate at 37°C for 4 hours according to manufacturer‘s protocol (Bio-Rad, Hercules, 
CA, USA).  Cell viability was determined by relative conversion of tetrazolium pigment, as 
detected by Absorbance490 measured on an ELISA microplate reader, as compared to cells under 
control conditions.   
 
Flow Cytometry   
To determine the cell cycle profile, cells were collected by keeping the supernatant and 
combining with trypsinized cells. Cells were washed in phosphate buffered saline (PBS) and fixed 
in 70% ethanol overnight at 4 degrees.  The next day cells were washed in PBS and incubated in 
DNA staining buffer (PBS pH 7.4 Triton X-100 0.1%, EDTA pH 7.4 0.5 mM, RNAse A 0.05 mg/ml) 
and propidium iodide 50 µg/ml for 30 min at room temperature in the dark.  Cells were analyzed 
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by flow cytometry using a Beckman Coulter FC500 (Beckman Coulter Inc., Brea, CA, USA) and 
analyzed using CXP v2.1 software (Beckman Coulter Inc.).  For cells transfected with CD20 
which is expressed on the membrane and Rb constructs CD20 FITC (Abcam, Cambridge, MA, 
USA) was added to trypsinized cells and incubated for 30 min, before DNA staining buffer was 
added.   
 
Luciferase assays 
Luciferase assays were performed using the Luciferase Assay System (Promega, Madison, WI, 
USA) with an E2F luciferase reporter construct (Panomics, Fremont, CA, USA) or cyclin E 
promoter luciferase reporter construct (Ma et al., 2003) according to the manufacturer‘s 
instructions. 
 
In Vitro Kinase Assays 
In vitro kinases assays were performed using purified phospho-p38α kinase, purified cyclin E-
Cdk2 kinase, or purified cyclin D1-Cdk4 kinase all from Cell Signaling.  Kinase assays were also 
performed using endogenous immunoprecipitated kinase from cells using IgG antibody (Sigma 
Aldrich) or phospho-p38 antibody (Cell signaling).  GST-tagged Rb small pocket domain with all 
sites mutated except for Ser567 (GST-Rb-SP∆4) or the C-terminus of Rb (GST-Rb-C) were 
purified and used as substrates.  0.5 µg of purified full length Rb was also used (QED Bioscience 
Inc, San Diego, CA, USA).  Kinase assays were performed by first pre-incubating the kinase with 
GST-Rb-C for 45 min and then adding in the GST-Rb- SP∆4 for an additional 45 min in a 40 µl 
kinase buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 150 µM ATP, 100 µCi of 
γ 
32
P-ATP).  GST-beads (Sigma Aldrich) were added for 30 min, rotating at room temperature.  
Beads containing phosphorylated substrate were washed twice for 5 min each using incomplete 
kinase buffer.   
 
TUNEL 
  
53 
 
TUNEL staining was performed using the In Situ Cell Death Detection Kit (Roche Diagnostics 
Corporation, Basel, Switzerland).  Cells were plated on Permonox Lab-Tek Chamber Slides 
(Elextron Microscopy Sciences, Hatfield, PA, USA ).  To analyze the slides, wells were washed 
with PBS, fixed with 4% paraformaldehyde/PBS (pH 7.4) for 30 min at room temperature, washed 
with PBS, permeabilized with 0.1% Triton X–100, 0.1% sodium citrate) for 5 min on ice, washed 
with PBS, incubated with TUNEL reagent for 1 h at 37 degrees, washed with PBS, mounted with 
Vectashield Hardset with DAPI (Vector Laboratories, Inc, Burlingame, CA, USA), and a cover slip 
was applied.  Pictures were taken with an Olympus Fluorescence BX51 microscope and data was 
analyzed using image J software.     
 
2.4 Results 
  
Loss of Rb triggers apoptosis in melanocytes 
It is important to distinguish between inactivation of Rb by partial hyperphosphorylation and loss 
of Rb.  RB is rarely deleted in cancers, yet Rb is hyperphosphorylated in virtually all tumors.  Most 
melanomas overexpress cyclin D1, which functionally inactivates Rb without causing apoptosis.  
Interestingly, cancers in which RB is deleted such as retinoblastomas have large amounts of 
apoptosis (Harbour, 2006).  Loss of Rb leads to apoptosis in many tissues, suggesting that there 
is an inherent pressure for organisms to eliminate aberrant cells that lack Rb (Clarke et al., 1992; 
Jacks et al., 1992; Lee et al., 1992).   
 
Functional and reversible inactivation of Rb by Cdk-mediated hyperphosphorylation, as occurs 
during normal cell division and in most proliferating cancer cells, does not induce cell death in 
melanoma cells (Figure 2.2 A).  In contrast, complete and irreversible inactivation of Rb by RNAi-
mediated depletion of the protein induced cell death both in Mel202 cells and in primary 
melanoma cells (Figure 2.2 A-C).  This is consistent with previous work demonstrating that 
specifically knocking out Rb from cells such as melanocytes or IMR90 human fibroblasts led to 
cell death (Young and Longmore, 2004b; Yu et al., 2003).   
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Genotoxic stress induces apoptosis in melanoma cells  
To explore why these mechanisms for inactivating Rb that have been assumed to be functionally 
equivalent result in such strikingly different phenotypic outcomes, we developed an experimental 
model system in which Rb degradation and apoptosis were induced by genotoxic stress in 
Mel202 cells, which have been extensively characterized and shown to be wildtype for Rb and 
p53 (Sun et al., 2005).  At low concentrations, the DNA damaging agent etoposide resulted in 
stabilization of p53, hypophosphorylation of Rb, and cell cycle arrest as expected (Figure 2..  We 
wondered if slightly higher concentrations of etoposide would continue to arrest cells or lead to 
cell death.  Growth curves and BrdU assays revealed that over time etoposide halted proliferation 
(Figures 2.4 and 2.5).  However, it was still unclear if the cells were arresting or dying.  To 
address this question, we investigated markers of cell death.  Cleavage of caspase 3, an indicator 
of initiation of apoptosis, was increased in etoposide-treated cells (Figure 2.6 A).  Furthermore, 
PARP cleavage, a hallmark of apoptosis, was increased over time with etoposide treatment 
(Figure 2.6 B).  MTS assays revealed that etoposide treatment led to death (Figure 2.6 C).  
Finally, the sub G1 (the apoptotic) population of cells increased with etoposide treatment when 
propidium iodide was used to study the cell cycle (Figure 2.6 D).  Similar results were obtained 
using low passage uveal melanocytes from two different patients (Figure 2.7) and U2OS 
osteosarcoma cells (Figure 2.8).  Taken together, these findings reveal that while low levels of 
genotoxic stress result in arrest, higher levels induce apoptosis. 
 
Genotoxic stress leads to hyperphosphorylation of Rb 
Next, we investigated the phosphorylation status of Rb during etoposide treatment to determine if 
etoposide leads to hypophosphorylation or hyperphosphorylation of Rb.  We initially hypothesized 
that etoposide would lead to hypophosphorylation of Rb because  at low levels etoposide induces 
p53 phosphorylation, causing p21
Cip1 
upregulation, which results in reversible 
hypophosphorylation of Rb and cell cycle arrest (Strobeck et al., 2000; Valentini et al., 2007).  
Using higher levels of etoposide, we found unexpectedly that apoptosis was accompanied not by 
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hypophosphorylation of Rb, but instead hyperphosphorylation of Rb in a dose-dependent manner 
(Figure 2.9 A).  We confirmed that this hyperphosphorylation of Rb occurred not only in the 
Mel202 cells but also in uveal melanocytes cells (Figure 2.9 B).  While low levels of genotoxic 
stress lead to hypophosphorylation of Rb and cell cycle arrest, we found that increased genotoxic 
promotes hyperphosphorylation of Rb.   
 
Genotoxic stress triggers phosphorylation of Rb by p38  
To determine which kinase catalyzes the phosphorylation of Rb in etoposide-treated melanoma 
cells we started by evaluating Cdks that phosphorylate Rb during cell division.  Inhibitors of Cdk2 
and Cdk4 did not block Rb hyperphosphorylation induced by etoposide (Figure 2.10 A-B).  The 
Cdk2 inhibitor was able to inhibit serum starvation induced hyperphosphorylation confirming that 
the inhibitor was active (Figure 2.10 C).  Additionally, kinase assays were performed to confirm 
that the Cdk2 and Cdk4 inhibitors were active (Figure 2.10 D-E).  This led us to hypothesize that 
p38, a MAPK member which is activated by etoposide might mediate this phosphorylation (Olson 
and Hallahan, 2004; Pillaire et al., 2000).  In recent years, p38 has been shown to phosphorylate 
Rb in response to stress and death receptor signaling in multiple cell types, for example in 
irradiated prostate cancer cells (Bowen et al., 2002), in sodium salicylate-treated colon cancer 
cells (Lee et al., 2003), in FasL-induced cerebellar granule neurons (Hou et al., 2002), in Jurkat 
lymphocytic cells (Wang et al., 1999) and in Fas-induced murine hepatocyte AML12 cells (Cho et 
al., 2010).  First, we investigated whether or not p38 phosphorylated Rb in our system of 
etoposide-stressed melanoma cells.  SB 203580 [4-(4´-fluorophenyl)-2-(4´-methylsulfinylphenyl)-
5-(4´-pyridyl) imidazole], which acts as a competitive inhibitor of ATP binding, specifically inhibits 
p38α and p38β.  It has no significant effects on ERKs, JNKs, p38γ or p38δ at the concentrations 
used (Goedert et al., 1997; Kuma et al., 2005).  The interaction between SB 203580 and p38α 
and p38β is due to its specificity for residue Thr106 near the ATP-binding pocket which is 
replaced by a bulky methionine residue in p38γ and p38δ (Cuadrado and Nebreda).  SB 203580 
potently inhibited Rb phosphorylation suggesting that p38 is responsible for phosphorylating Rb 
during genotoxic stress (Figure 2.11 A).  We confirmed that the p38 inhibitor was working 
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(Figure 2.10 C and Figure 2.11 B).  Since SB 203580 inhibits both p38α and p38β we used 
RNAi to determine which isoform of p38 was phosphorylating Rb in our system.  siRNA-mediated 
knock down of p38α, but not p38β, inhibited hyperphosphorylation of Rb suggesting that p38α 
phosphorylates Rb in response to genotoxic stress (Figure 2.11 C).  Consistent with these 
findings, p38 underwent activating phosphorylation during etoposide treatment (Figure 2.11 D).  
Importantly, chemical inhibition of p38 substantially reduced etoposide-induced apoptosis by flow 
cytometry (Figure 2.12 A) and by TUNEL (Figure 2.12 B).  Taken together, these data suggest 
that during genotoxic stress p38 phosphorylates Rb, ultimately leading to apoptosis.   
 
Activation of p38 by MKK3 leads to hyperphosphorylation of Rb and cell death 
Etoposide induces global stress which activates many signaling pathways such as caspases, 
PI3K/Akt, myc, ERK1/2, ATM, and NF-kB (Benjamin et al., 1998; Fu et al., 2008b; Liu et al., 2006; 
Morotti et al., 2006).  Since we determined the p38 pathway plays a role in Rb-mediated 
apoptosis, we next directly activated p38 in order to rule out any off-target effects that may be 
caused by etoposide treatment.  MKK3, a MAPKK, is a highly specific direct upstream activator 
for p38α, p38γ, and p38δ, but not p38β (Cuadrado and Nebreda).  MKK3 specifically activates 
p38 by dual phosphorylation of the Thr-X-Tyr motif.  Adenoviral activation of endogenous p38 by 
Ad-MKK3 led to hyperphosphorylation of Rb, which was inhibited by a p38 inhibitor and was 
similar to the effect of etoposide treatment (Figure 2.13 A-B).  Furthermore, MKK3-, but not 
cyclin D1--treated cells underwent increased apoptosis as shown by flow cytometry (Figure 2.13 
C).  Therefore, direct activation of endogenous p38 by expression of the upstream effector MKK3 
triggers phosphorylation of Rb and induces apoptosis in a manner that is  indistinguishable from 
etoposide treatment. 
 
p38 phosphorylates Rb on Ser567 during genotoxic stress 
We sought to determine which site on Rb was being phosphorylated during genotoxic and p38-
mediated stress.  Cyclin-Cdks were not responsible for phosphorylating Rb during stress and so 
we hypothesized their corresponding C-terminal phosphoacceptor sites would also not be 
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involved.  Instead, we turned to a pocket site, Ser567, as it is the only site on Rb that is not 
phosphorylated during the normal cell cycle (Lees et al., 1991).  An Rb Ser567-phospho-specific 
antibody showed that this site was phosphorylated in response to etoposide (Figure 2.10 A) and 
Ad-MKK3 (Figure 2.13 A).  A p38 inhibitor (Figures 2.11 A and 2.13 A), but not a Cdk2 inhibitor, 
(Figure 2.10 A) inhibited phosphorylation of Ser567.  This suggests that p38, but not cyclin-Cdks, 
is involved in phosphorylation of Ser567 on Rb in response to genotoxic stress. 
 
Ser567 on Rb plays a unique role during genotoxic stress-induced apoptosis 
We wondered if phosphorylation of Rb on Ser567 played a role in genotoxic stress-induced 
apoptosis.  Flow cytometry was performed using a mutant in which seven phosphoacceptor sites; 
Ser780, Ser788, Ser795, Ser807, Ser811, Thr821, and Thr825 were mutated to alanines (RbΔ7), 
leaving only three remaining functional phosphoacceptor sites; Ser567, Ser608, and Ser612.  
Etoposide treatment of RbΔ7 expressing cells led to apoptosis, evidence that the C-terminal sites 
are not important during etoposide-induced apoptosis (Figure 2.14).  Next, we used a mutant that 
would block phosphorylation of Ser567.  The Ser567 phosphoacceptor site mutant in which 
Ser567 is mutated to an alanine (RbΔ567) is unique in that it mimics, rather than blocks, Ser567 
phosphorylation.  This mutant could not be used to assess how blocking Ser567 phosphorylation 
affects Rb function.  Instead, we used an Rb mutant in which proline568 was substituted with an 
alanine (RbΔ568), which remains partially active while blocking Ser567 phosphorylation (Harbour 
et al., 1999; Ma et al., 2003).  Ectopic expression of RbΔ568, but not wildtype Rb or an Rb mutant 
in which Ser780, a C-terminal site, was substituted with an alanine preventing phosphorylation 
(RbΔ780), inhibited apoptosis in cells treated with etoposide (Figure 2.15 A) and cells treated 
with Ad-MKK3 (Figure 2.15 B).  Phosphorylation of Ser567 on Rb is not only important to 
promote p38-induced death, but it is specifically required as inhibition of Ser567 phosphorylation 
inhibits apoptosis.   
 
p38 phosphorylates Rb on Ser567 by a novel mechanism 
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While p38 has been shown to phosphorylate Rb (Wang et al., 1999), it remains unclear whether 
p38 phosphorylates Rb by the same mechanism previously shown for Cdks involving a 
hierarchical series of conformational changes or by a novel mechanism (Harbour et al., 1999).  
We performed in vitro kinase experiments to confirm the ability of p38 to phosphorylate Rb 
directly (Figure 2.16 A).  Both recombinant p38α and endogenous p38, immunoprecipitated from 
melanoma cells treated with etoposide, resulted in robust phosphorylation of Rb in vitro.  As our 
lab showed previously (Harbour et al., 1999), cyclin E-Cdk2 can phosphorylate Rb on Ser567 
only in the presence of the phosphorylated Rb C-terminus.  In contrast, p38 did not require the C-
terminus for efficient phosphorylation of Ser567; instead, p38 phosphorylated this residue more 
efficiently in the absence of the C-terminus (Figure 2.16 B-C).  This indicated that p38 
phosphorylates Rb on Ser567 through a unique mechanism unlike that of Cdks.  The mechanistic 
difference in which Cdks and p38 phosphorylate Rb sheds light on how these two kinases 
differentially regulate Rb. 
 
Phosphorylation of Rb by p38 disrupts the E2F1-Rb interaction and triggers E2F1-
mediated apoptosis   
For many years, Rb was thought to be bound to E2F when arresting the cell cycle and released 
from E2F after being phosphorylated by cyclin-Cdks, allowing for cell cycle progression.  While 
free E2F does promote cell division, it also transactivates pro-apoptotic genes making this model 
very inefficient.  Recent work suggests that Rb continues to stay bound to E2Fs throughout the 
cell cycle (Ezhevsky et al., 2001; Ezhevsky et al., 1997; Wells et al., 2000; Wells et al., 2003).  
So, under what circumstances are E2Fs completely released from Rb?  We reasoned that stress-
related phosphorylation of Rb would be unique in its ability to release E2Fs that could then 
activate apoptotic genes, and that this could account for the apoptosis that occurs when p38 
phosphorylates Rb.  We chose to focus on E2F1, as it is the primary E2F family member involved 
in the apoptotic response and is upregulated in response to etoposide (Ginsberg, 2002).  
However, we do not rule out the possibility that other E2F family members may play a role (Dick 
and Dyson, 2003; Xu et al., 2007).  To this end, we activated endogenous p38 in cells by 
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expressing MKK3, and used co-immunoprecipitation experiments to evaluate the interaction 
between E2F1 and ectopically expressed Rb.  As expected, phosphorylation of Rb by p38 
disrupted the interaction between Rb and E2F1 (Figure 2.17 A).  The release of E2F from Rb 
repression by activated p38α allowed it to activate E2F-responsive promoters (Figure 2.17 B).  
We confirmed this finding by performing similar luciferase assays with  MKK3, the direct upstream 
activator of p38 and found that in both Mel202s (Figure 2.17 C) and C33A cervical cancer cells, 
(Figure 2.17 D) MKK3 promotes release of E2F from Rb.  Rb∆567, which mimics Ser567 
phosphorylation, led to activation of E2F-responsive promoters, whereas the Rb∆568 construct, 
which blocks Ser567, phosphorylation repressed E2F (Figure 2.17 E).  Taken together these 
data suggest that phosphorylation of Rb on Ser567 by p38 derepresses E2F1-mediated 
transactivation.  Further, RNAi-mediated knock down of E2F1 inhibited Ad-MKK3-associated 
apoptosis by TUNEL, confirming that p38 induced apoptosis through release of E2F1 (Figure 
2.18 A-B). 
 
Phosphorylation of Rb during stress is p53-independent 
We have shown that Mel202, and other melanoma cell lines, have wildtype, functionally active 
p53 which is induced by DNA damage (Sun et al., 2005).  Recognizing that p53 is activated by 
etoposide as part of the DNA damage response (Lowe et al., 1993), we wished to determine 
whether p53 was required for p38-mediated Rb phosphorylation.  Surprisingly, knock down of p53 
by RNAi had no effect on the phosphorylation status of Rb induced by etoposide (Figure 2.19 A).  
Further, phosphorylation of Rb in response to Ad-MKK3 treatment was independent of p53 
(Figure 2.19 B).  These data suggest that p53 does not play a role in p38-mediated Rb 
hyperphosphorylation .   
 
p38-mediated apoptosis is p53-dependent 
Stress can lead to cell death in a p53-dependent or a p53-independent manner (Bacus et al., 
2001; Fattman et al., 1998; Lemaire et al., 2005; Macleod et al., 1996; Wang et al., 2008).  
However, p53-dependent apoptosis tends to be due to genotoxic stress, while p53-independent 
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death usually results from growth factor deprivation (Peled et al., 1996).  Recognizing that we 
were looking at a genotoxic stress setting and that both etoposide and p38 can activate p53 
(Bulavin et al., 1999; Lowe et al., 1993), we wished to determine if p53 contributed to genotoxic 
stress-induced apoptosis.  As hypothesized, knock down of p53 by RNAi did inhibit etoposide-
induced cell death (Figure 2.20 A).  Similar results were observed in Ad-MKK3-treated cells 
(Figure 2.20 B).  These data indicate that p53 cooperates to promote apoptosis during genotoxic 
stress. 
 
2.5 Discussion  
 
In this study, we demonstrate that p38, a MAPK member, phosphorylates Rb on residue Ser567 
in response to genotoxic stress.  The ability of p38, but not Cdks, to efficiently phosphorylate Rb 
on Ser567 may provide a key to understanding the different effects that p38 versus Cdks have on 
Rb.  Phosphorylation of Rb by Cdks occurs through a hierarchical series of phosphorylation 
events each triggering successive conformational changes that enable further phosphorylation in 
a stepwise manner (Brown et al., 1999; Harbour et al., 1999; Lundberg and Weinberg, 1998; 
Zhang et al., 2000).  Previous work has demonstrated that Ser567 is the site least efficiently 
phosphorylated by Cdks (Harbour et al., 1999).  Phosphorylation of Ser567 by Cdks requires prior 
phosphorylation of the C-terminus, which contains Cdk docking sites that bring cyclin-Cdk 
complexes into proximity of Ser567 through an intramolecular interaction between the C-terminus 
and the pocket (Harbour et al., 1999).  Ser567 has not been reported to be phosphorylated in 
cycling cells (Lees et al., 1991), suggesting that it is not phosphorylated during normal cell cycle 
progression.  Herein we show that p38 efficiently phosphorylates Ser567 under conditions 
favoring apoptosis.  Consistent with this finding, Nath and colleagues determined that an Rb 
mutant in which all available phosphorylation sites except Ser567 were mutated to prevent their 
phosphorylation was unable to rescue p38-mediated inactivation of Rb (Nath et al., 2003).  
Similarly, von Willebrand and colleagues reveal that a phosphorylation-defective Rb mutant was 
not resistant to ubiquitination despite elimination of most of the phosphorylation sites; Ser567 was 
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one of the few sites that was not mutated (von Willebrand et al., 2003).  Importantly, we found 
that phosphorylation on Ser567 by p38 does not depend on the intramolecular interactions and 
conformational changes associated with Cdk-mediated phosphorylation.  This would allow p38 to 
bypass Cdk-mediated phosphorylation of the C-terminus and directly regulate Rb in a cell cycle-
independent manner during apoptotic signaling.  The ability of p38 to phosphorylate Ser567 may 
be due to its small size, allowing it to access Ser567, which is located in a recess at the interface 
of the A and B boxes of the pocket, where it would likely be inaccessible to the much larger 
cyclin-Cdk complexes under normal circumstances (Harbour et al., 1999; Lee et al., 2002).  Our 
data demonstrate that Ser567 is necessary for stress-induced apoptosis, suggesting it is a critical 
node in the decision of cellular fate in response to an insult.   
 
While the paradigm in the Rb field promotes that Rb is bound to E2Fs when active or 
hypophosphorylated and E2F is released when Rb is inactivated by phosphorylation (Coller, 
2007), more recent work has shown that E2Fs indeed stay bound to Rb throughout the cell cycle 
(Ezhevsky et al., 2001; Ezhevsky et al., 1997; Wells et al., 2000; Wells et al., 2003) leading us to 
hypothesize that E2F1 is only released from Rb after Rb is degraded, not after inactivation.  To 
this end, we looked to see if Rb was bound to E2F1 during genotoxic stress to determine if Rb 
was being inactivated or disrupted in this setting.  Indeed phosphorylation of Rb by p38 disrupted 
the Rb-E2F1 interaction and derepressed E2F-mediated transactivation.  Ser567 phosphorylation 
specifically was required for the release of E2Fs from Rb, further implicating this site as a major 
regulator of cell fate.  This is supported by work revealing that Ser567 is the only phosphorylation 
site on Rb that, when phosphorylated or mutated, disrupts the A and B box interaction, 
destabilizes the pocket structure, and abrogates interaction with E2Fs (Harbour et al., 1999; Ma 
et al., 2003).  Further, crystallographic studies have shown that Ser567 mediates critical contacts 
between the A and B boxes, and that phosphorylation of this site would be predicted to 
destabilize the pocket structure and eliminate the E2F binding site (Lee et al., 2002; Lee et al., 
1998). 
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The p53 and Rb pathways are the two most commonly disrupted tumor suppressor pathways in 
cancer (Sherr, 2004; Sherr and McCormick, 2002).  The two pathways are firmly intertwined as 
E2F activation of p14
ARF
 and stabilizes p53 and p53 activates p21
Cip1
 leading to 
hypophosphorylation and activation of Rb, making it difficult to study one tumor suppressor 
without considering the other.  Furthermore p38 has been shown to directly phosphorylate p53 
and promote p53-dependent apoptosis in response to UV radiation (Bulavin et al., 1999).  
Therefore, we investigated the role of p53 in etoposide-treated melanoma cells.  While p53 did 
not contribute to the phosphorylation status of Rb, it did promote apoptosis in genotoxic-stressed 
melanoma cells.  This is consistent with our data demonstrating that E2F1 is released from Rb in 
response to etoposide which would promote p14
ARF
 transcription, stabilize p53, and allow for p53-
mediated apoptosis.   
 
Taken together, these findings suggest that p38 phosphorylates Rb through a novel, cell cycle-
independent mechanism and illuminates the way in which Rb coordinately regulates the cell cycle 
versus apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
63 
 
2.6 Figures 
 
 
 
 
 
 
 
 
 
Figure 2.1 Representation of the crystal structure of the pocket domain of Rb 
The A box, B box, Ser567 phosphoacceptor site, E2F binding site, and LxCxE site are shown in 
this illustration of the crystal structure of the Rb pocket domain.  Adapted from (Lee et al., 2002). 
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Figure 2.2 Loss of Rb leads to apoptosis 
(A)  Mel202 cells were transfected with scrambled siRNA or Rb siRNA, or with vectors expressing 
cyclin D1 and/or cyclin E to activate endogenous Cdks for 4 days and cell viability assays were 
performed.  (B) Cell viability assays were performed in MM28 primary melanoma cells using 
scrambled siRNA or Rb siRNA.  (C) Immunoblot analysis confirming effective knock down of Rb 
with siRNA in Mel202s after 4 days.  Tubulin was used as a loading control in all immunoblot 
experiments.   
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Figure 2.3 A low concentration of etoposide leads to G2/M arrest 
Mel202 cells were untreated or treated with 1.25 µM etoposide for 48 h and analyzed by flow 
cytometry.   
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Figure 2.4 Genotoxic stress halts proliferation 
12.5 µM of etoposide treatment halted cell growth in Mel202 cells as shown by growth curves. 
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Figure 2.5 Genotoxic stress inhibits proliferation  
12.5 µM of etoposide treatment inhibits cell proliferation in Mel202 cells as shown by BrdU 
experiments.   
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Figure 2.6 Genotoxic stress leads to cell death in Mel202 cells 
(A) Cleaved caspase 3 staining of Mel202 cells treated with or without 12.5 µM of etoposide for 
48 h.  (B) Mel202 cells were treated with 0, 0.6, 6, 12, 25 µM etoposide for 48 h and 
immunoblotted for cleaved PARP.  (C) Cell viability assays were performed in Mel202 cells that 
were untreated or treated with 12.5 µM of etoposide for 48 h.  (D) Flow cytometry was performed 
using Mel202 cells treated with 0, 1, 5, 12, 25 µM etoposide for 48 h.   
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Figure 2.7 Genotoxic stress leads to cell death in primary human uveal melanocytes 
Primary uveal melanocytes from two different patients were treated with or without 12.5 µM of 
etoposide for 48 h and analyzed by flow cytometry.  Almost 6 times more death occurred in the 
treated cells.   
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Figure 2.8 Genotoxic stress leads to cell death in osteosarcoma cells   
U2OS osteosarcoma cells were treated with or without 12.5 µM of etoposide for 48 h and 
analyzed by flow cytometry.  The amount of death doubled in the treated cells.   
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Figure 2.9 Genotoxic stress leads to hyperphosphorylation of Rb 
(A) Mel202 cells were treated with 12.5 µM etoposide for 0, 24, 48, 72 h and immunoblotted for 
Rb.  (B) Primary human uveal melanocytes were treated with 0, 1.5, 3, 6, 12.5, 25, 50 µM 
etoposide for 48 h and immunoblotted for Rb.   
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Figure 2.10 Cdks are not responsible for genotoxic stress-induced hyperphosphorylation 
of Rb 
(A) Mel202 cells were treated with 12.5 µM of etoposide and 0, 50, 100, or 500 µM of the Cdk2 
inhibitor, Roscovitine, for 48 h and then immunoblotted for total Rb and phospho-Rb-567. (B) 
Mel202 cells were treated with Cdk4 inhibitor and 12.5 µM etoposide for 48 h and immunoblotted 
for Rb. (C) Inhibition of serum starvation-induced hyperphosphorylation of Rb confirmed inhibitor 
activity in Mel202 cells.  Lane 1, serum for 24 h.  Lane 2, serum starved for 48 h, serum added 
back for 24 h.  Lane 3, serum starved for 48 h, serum added back for 24 h with p38 inhibitor.  
Lane 4, serum starved for 48 h.  Lane 5, serum starved for 48 h, serum added back for 24 h with 
Cdk2 inhibitor Roscovitine.  (D) In vitro kinase assay confirmed that the Cdk2 inhibitor was active.  
Kinase assay was blotted with phospho-Rb-795, a site known to be phosphorylated by Cdk2.  (E) 
In vitro kinase assay confirmed that the Cdk4 inhibitor was active.  Kinase assay was blotted with 
phospho-Rb-780, a site known to be phosphorylated by Cdk4.   
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Figure 2.11 Genotoxic stress triggers phosphorylation of Rb on Ser567 by p38α 
(A) Mel202 cells were treated with p38 inhibitor SB203580 for 48 h and immunoblotted for total 
Rb and phospho-Rb-567.  (B) In vitro kinase assay confirmed that the p38 inhibitor was active.  
Kinase assay was blotted with phospho-Rb-807-811 and total Rb. (C) siRNA against p38α or 
p38β was transfected into Mel202 cells at a final concentration of 50 nM for 72 h, all samples 
were treated with 12.5 µM of etoposide for 48 h, and immunoblotted for Rb.  (D) Mel202 cells 
were treated with or without 12.5 µM of etoposide for 48 h and immunoblotted for phospho-p38.   
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Figure 2.12 p38 inhibitor inhibits genotoxic stress-induced death  
(A) Mel202 cells were treated with 4 µM etoposide, 30 µM of p38 inhibitor, or both for 48 h.  
Propidium iodide was used in order to determine the sub-G1 DNA content by flow cytometry.  (B) 
Mel202 cells were treated with 12.5 µM etoposide, 30 µM of p38 inhibitor, or both for 48 h.  
TUNEL staining was performed to determine the percent of apoptotic cells.   
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Figure 2.13 MKK3 promotes hyperphosphorylation of Rb and apoptosis in a similar 
manner to genotoxic stress 
(A) Mel202 cells were treated with Ad-LacZ or Ad-MKK3 at an MOI of 100 with or without 30 µM 
of p38 inhibitor and immunoblotted for Rb, phospho-Rb-567 or phospho-p38.  (B) Mel202 cells 
were treated with Ad-GFP, Ad-cycD1, or Ad-MKK3 at an MOI of 30 for 48 h and immunoblotted 
for total Rb, phospho-p38, or cyclin D1.  (C) Mel202 cells were treated with Ad-cycD1 or Ad-
MKK3 at an MOI of 30 for 48 h.  Flow cytometry was performed using propidium iodide staining to 
determine the percent of cells in sub-G1.   
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Figure 2.14 C-terminal sites are not necessary for genotoxic stress-induced induced death 
Flow cytometry was performed in Mel202 cells using a mutant in which seven C-terminal sites, 
Ser780, Ser788, Ser795, Ser807, Ser811, Thr821, and Thr825 were mutated to alanines (RbΔ7) 
leaving only three remaining phosphoacceptor sites; Ser567, Ser608, and Ser612.  Cells were 
transfected with CD20 and SKTT control or RbΔ7, the next day 12.5 µM of etoposide was added 
to the media.  Cells were collected 48 h after etoposide treatment.   
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Figure 2.15 Phosphorylation of Rb on Ser567 is necessary for stress-induced death  
(A) Mel501 cells were transfected with SKTT control, Rb, Rb∆780, or Rb∆568 for 72 h and 
treated with 12.5 µM etoposide for 48 h.  TUNEL staining was performed.  (B) Mel501 cells were 
transfected with SKTT control, Rb, or Rb∆568 for 72 h and treated with Ad-MKK3 or Ad-LacZ 
MOI 15 for 48 h.  TUNEL staining was performed.  Data were normalized to Rb568 for each 
virus.    
 
  
  
78 
 
 
 
 
 
Figure 2.16 p38 phosphorylates Rb directly and by a different mechanism than cyclin E-
Cdk2 
(A) In vitro radioactive kinase assays revealed that p38 directly phosphorylated Rb.  Top Panel: 
Purified p38α phosphorylated 0.5 µg of purified full length Rb.  Bottom Panel: Endogenous 
phospho-p38 immunoprecipitated from Mel202 cells phosphorylated 0.5 µg of purified full length 
Rb.  (B) Non-radioactive in vitro kinase assays were performed using 20 ng of purified p38 or 
cyclin E-Cdk2 kinase.  GST-SP∆4 (small pocket of Rb with all phosphoacceptor sites except 
Ser567 mutated to an alanine) and GST-C (C-terminus of Rb) were used as substrates.  Lanes 1, 
4, and 7 had 3.2 µg of GST-C, lanes 2 and 5 had no GST-C, lanes 3 and 6 had 1.6 µg of GST-C.  
1 µg of GST- SP∆4 was used. Samples were immunoblotted with an antibody against phospho-
Rb-567 or an antibody against GST which recognizes both GST-SP∆4 and GST-C.  The GST-C 
and GST-SP∆4 Rb fragments have been shown to interact in vitro (Harbour et al., 1999).  GST-C 
is necessary for efficient phosphorylation of the small pocket by Cdk2, but is not required for 
phosphorylation by p38.  (C) A graphical representation of the band intensity of the phospho-Rb-
567 antibody in (B).   
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Figure 2.17 Phosphorylation of Rb by p38 derepresses E2F1-mediated transactivation   
(A) Mel202 cells were transfected with Rb alone or with MKK3 for 48 h and immunoprecipitation 
for Rb was performed.  The immunoprecipitation was immunoblotted for E2F1.  Total lysates 
were immunoblotted for total Rb and E2F1.  (B) An E2F reporter construct was used in luciferase 
assays.  Empty vector (pCDNA3), Rb, E2F1, and constitutively active p38α expression constructs 
were transfected into Mel202 cells.  The star represents constitutively active p38α.  (C) An E2F 
reporter construct was used in luciferase assays.  Empty vector (pCDNA3 and RSV2), Rb, E2F1, 
and MKK3 expression constructs were transfected into Mel202 cells.  (D) An E2F reporter 
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construct was used in luciferase assays.   Empty vector (pCDNA3 and RSV2), Rb, E2F1, and 
MKK3 expression constructs were transfected into C33A cervical cancer cells that lack functional 
Rb.  (E) The E2F responsive Cyclin E reporter construct was used in luciferase assays.  Empty 
vector (pCDNA3), Rb, Rb∆567, Rb∆568, and E2F1 expression constructs were transfected into 
Mel202 cells.   
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Figure 2.18 Phosphorylation of Rb by p38 leads to E2F1-mediated apoptosis  
(A) Scrambled or E2F1 siRNA was used at a final concentration of 50nM for 72 h in Mel501 cells.  
The cells were treated with 12.5 µM of etoposide for 48 h and TUNEL staining was performed.  
(B)  Knock down of E2F1 by siRNA was confirmed in Mel501 cells.  50 nM of scrambled siRNA, 
25 nM of E2F1 siRNA, or 50 nM of E2F1 siRNA were transfected for 72 h.   
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Figure 2.19 p38-mediated phosphorylation of Rb is p53-independent  
(A) Mel202 cells were treated with 12.5 µM of etoposide for 48 h.  Scrambled or p53 siRNA was 
used at a final concentration of 50 nM for 72 h.  p53 expression vector or empty vector were 
transfected for 72 h.  Samples were immunoblotted with antibodies against Rb and p53.  (B) 
Mel202s were transfected with siRNA against p53 or scrambled siRNA for 72 h and treated with 
Ad-MKK3 MOI of 15 for 48 h.  Samples were immunoblotted with antibodies against Rb and p53.   
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Figure 2.20 p38- induced apoptosis is p53-dependent 
(A) Mel202 cells were transfected with p53 siRNA or scrambled siRNA for 72 h.  Cells were 
treated with 12.5 µM of etoposide for 48 h and TUNEL staining was performed.  (B) Mel202s 
were transfected with p53 siRNA or scrambled siRNA for 72 h and treated with Ad-LacZ or Ad-
MKK3 at an MOI of 15.  TUNEL staining was performed.   
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Chapter 3 
 
p38 phosphorylation of Ser567 on Rb in response to genotoxic stress leads to Rb-Hdm2 
interaction and apoptosis 
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3.1 Abstract 
 
While Rb has been classically studied in the cell cycle setting, this important tumor suppressor 
also regulates apoptosis.  Cells were stressed with a DNA damaging reagent which resulted in 
degradation of Rb.  Phosphorylation of Rb by the stress kinase p38, but not by the cell cycle 
kinase cyclin D-Cdk4, led to an increased interaction between Rb and Hdm2.  Specifically, 
phosphorylation of Ser567 during stress enhanced the Rb-Hdm2 interaction.  We provide new 
insights into the relationship between the oncoprotein Hdm2 and the tumor suppressors p53 and 
Rb and implicate Ser567 phosphorylation as a key event in the cellular response to stress. 
Consistent with our in vitro work, phosphorylation of Ser567, but not C-terminal sites, correlated 
with poor prognosis in uveal melanoma patients.  Our data suggest that Ser567 may serve as a 
biomarker of stress in cancer patients.     
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3.2 Introduction 
 
Rb was named the first tumor suppressor for the ability to inhibit cell division (Friend et al., 1986; 
Goodrich et al., 1991; Knudsen et al., 1998; Weinberg, 1991).  In order for cells to divide, Rb 
must be temporarily inactivated by cyclin-Cdks, which phosphorylate Rb at up to 16 Ser/Thr-Pro 
phospho-acceptor sites, thereby allowing cells to traverse from G1 into S phase (Chen et al., 
1989; Hinds et al., 1992; Lin et al., 1991; Lundberg and Weinberg, 1998; Serrano et al., 1993).  
During cell cycle progression, Rb is phosphorylated by cyclin D/Cdk4 in early G1, cyclin E/Cdk2 in 
late G1, and finally by cyclin A/Cdk2 in S phase (DeCaprio et al., 1992; Kato et al., 1993; Sherr, 
1996).  Regulation of the cell cycle by Rb is intricately linked to the binding of E2F transcription 
factors (Stevaux and Dyson, 2002).  Rb can bind the activators, E2F1-3 and the repressor, E2F4 
to regulate transcription (Stevaux and Dyson, 2002).  Rb inhibits the E2F transactivation function 
by directly binding and masking the transactivation domain and by recruiting chromatin 
remodeling factors to alter local chromatin structure to an inhibitory state (Almasan et al., 1995; 
Chellappan et al., 1991; Dyson, 1998; Hsieh et al., 1997; Irwin et al., 2000; Morgenbesser et al., 
1994; Nevins, 1998; Shan et al., 1994; Tsai et al., 1998).   
 
As well as acting as a cell cycle regulator, Rb also functions as an anti-apoptotic factor.  Loss of 
Rb causes apoptosis in melanocytes as well as other cell types and Rb knockout mice have 
increased apoptosis (Bremner et al., 2004; Chau and Wang, 2003; Wu et al., 1996).  To study the 
coordinate roles of Rb in cell cycle and apoptosis, we have selected the melanocyte lineage, 
where a number of observations point to a critical role for Rb in differentiation, survival and tumor 
suppression.  The Cdk4/6 inhibitor p16
Ink4a 
is frequently mutated in familial melanoma, and 
individuals with RB gene mutations are at increased risk for melanoma (Begg et al., 2005; 
Halaban, 1999; Luca et al., 1995; Reed et al., 1995; Reymond and Brent, 1995).  Virtually all 
mouse models of melanoma require inhibition of Rb, such as by overexpression of large T 
antigen or by inactivation of p16
Ink4a
, which allows unrestricted phosphorylation of Rb by Cdk4/6 
(Castellano and Parmiani, 1999; Yu et al., 2003).  Additionally, activating mutations in the RAS-
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RAF-MAPK pathway, which inhibit Rb through activation of cyclin D, are ubiquitous in 
melanocytic tumors (Gupta et al., 2005; Pollock et al., 2003). 
 
Hyperphosphorylation of Rb caused by a stress insult (Chapter 2) was accompanied by 
degradation of Rb.  This degradation of Rb lends mechanistic insight into why cell die rather than 
arrest after genotoxic stress.  We investigated the pathway that mediates Rb degradation and cell 
death in response to stress.  While enzyme mediated-degradation was also considered, we found 
the degradation of Rb to be due to the proteosome.  We focused on Hdm2, an E3 ligase that has 
been shown to play a role in the degradation of Rb.  Hdm2 binds the C-terminus of Rb and 
ubiquitinates Rb, targeting it for degradation by the proteosome (Sdek et al., 2004; Xiao et al., 
1995).   
 
The mechanism of the Rb-Hdm2 interaction was investigated.  We hypothesized that 
phosphorylation events drove this interaction as phosphorylation is key in regulating Rb.  The 
residue Ser567 on Rb was of particular interest as it is the only phosphorylation site on Rb that, 
when phosphorylated or mutated, leads to localization of Rb in the cytoplasm rather than the 
nucleus (Ma et al., 2003).  We found that phosphorylation of Rb on Ser567 leads to Hdm2-
mediated degradation of Rb and apoptosis. 
 
We determined that phosphorylation of Ser567 is important in human cancer.  Uveal melanoma is 
the most common eye cancer (Onken et al., 2004).  While presentation in the uveal tract of the eye 
accounts for only 4% of all melanoma, like cutaneous melanoma, it is highly resistant to radiation 
and chemotherapy and is therefore very difficult to treat.  Half of uveal melanoma cases 
metastasize hematogenously to the liver where median survival is less than 6 months.  There will 
be an estimated 200 deaths due to this disease in 2010 in the United States alone (ACS, 2010) 
(Gragoudas et al., 1991).  Samples of primary uveal melanoma patients were obtained and 
increased phosphorylation of Rb on Ser567 correlated with poor prognosis in uveal melanoma by 
IHC.  Our lab developed a peptide made up of Ser567 and the surrounding residues which mimics 
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the effect of Ser567 phosphorylation as a proof of principle for Rb targeted therapies.  The peptide 
resulted in massive apoptosis of cancer cells.  However, when Ser567 and Pro568 were mutated to 
alanines in an otherwise identical peptide the cells did not die, confirming that the pro-apoptotic 
activity is specific to Ser567.  Understanding the mechanism behind Rb-mediated apoptosis in 
response to genotoxic stress could lead to life saving treatments.   
 
3.3 Materials and methods  
Please refer to Chapter 2 for materials and methods that have already been discussed. 
Cell culture 
A375 cutaneous melanoma, 10T/2 mouse fibroblasts, 92.1 uveal melanoma, and MCF-7 and MB-
MDA-231 breast cancer cells were grown in DMEM (Invitrogen) supplemented with 10% fetal 
bovine serum (Sigma Aldrich), L-glutamine/antibiotics/anti-mycotics (Mediatech) under conditions 
of 5% carbon dioxide and 21% oxygen. 
 
Inhibitors 
When indicated, cells were treated with Hdm2 E3 Ligase Inhibitor 373225 (EMD), Z-VAD-FMK 
pan caspase inhibitor (Sigma Aldrich), or MG132 proteosome inhibitor (Sigma Aldrich). 
 
Constructs and siRNA 
An Rb-A expression plasmid was used (Harbour et al., 1999). Validated siRNA against Hdm2 or 
scrambled control (Ambion) were used.   
 
Antibodies 
Antibodies against Gal4 and Hdm2 were from Santa Cruz Biotechnology, Inc.  Phospho-PKC-δ 
was from Cell Signaling.   
 
Immunohistochemical Staining   
  
94 
 
Immunohistochemistry (IHC) was performed as previously described (Brantley et al., 2002).  Rb-
phospho-Ser567 polyclonal rabbit antibody was applied at a dilution of 1:50 (developed for our 
lab by Bethyl Laboratories as previously described (Ma et al., 2003).  Rb-phospho-807-711 (Cell 
Signaling) was applied at a dilution of 1:100.  Nibrin (Cell Signaling) was applied at a dilution of 
1:75 as previously described (Ehlers and Harbour, 2005).   
 
Ser567 Peptides 
Transducible peptides were synthesized by Biomolecules Midwest (Waterloo, IL) as previously 
described and made up in serum-free media (Harbour et al., 2002).  The Tat-S567 peptide 
comprises the 12 amino acid Tat transduction domain followed by a 20 amino acid fragment 
corresponding to amino acids 558 through 577 of the human Rb protein.  The Tat-S567A was 
identical to the Rb567 peptide except for the substitution of an alanine for the serine 
corresponding to amino acid 567 of the parent protein.  The Tat-S567A/P568A was identical to 
the Rb567 peptide except for the substitution of two alanines for the serine and proline residues 
corresponding to amino acids 567 and 568 of the parent protein.  The Tat peptide was comprised 
only the Tat transduction domain.   
 
3.4 Results 
 
Genotoxic stress leads to degradation of Rb 
In our experiments, genotoxic stress resulted not only in hyperphosphorylation of Rb, (Chapter 2) 
but also in a precipitous decline in total Rb protein levels, suggesting that p38-mediated 
phosphorylation causes degradation of Rb (Figure 3.1).  Indeed, after 72 h of etoposide 
treatment, over half of the Rb in Mel202 uveal melanoma cells had been degraded (Figure 3.1 
A).  This result was confirmed in primary uveal melanocytes (Figure 3.1 B), in a second uveal 
melanoma cell line, 92.1 cells (Figure 3.1C), and in A375 cutaneous melanoma cells (Figure 3.1 
D).  This finding was not specific to the melanocyte lineage.  Etoposide treatment resulted in Rb 
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degradation in U2OS osteosarcoma cells, 10T/2 mouse fibroblasts, and MCF-7 and MB-MDA-
231 breast cancer cells (Figure 3.2 A-D).    
 
Activation of p38 leads to Rb degradation 
Etoposide activates many pathways therefore, Ad-MKK3 was used to directly active endogenous 
p38 and Rb protein levels were assessed.  In corroboration with the etoposide data, Ad-MKK3 
treatment also led to degradation of Rb (Figure 3.3).   
 
Degradation of Rb during genotoxic stress is not due to enzymatic cleavage  
We wondered if caspases were responsible for the Rb degradation seen in response to genotoxic 
stress.  Rb is cleaved by caspase 3 and 7 on the DEAD886 recognition motif in the C-terminus 
releasing a p48 fragment made up of the N-terminus of Rb that is cytoplasmic and a p68 fragment 
made up of the large pocket of Rb that is nuclear and can still bind DNA but no longer interacts with 
E2F1 (An and Dou, 1996, Fattman, 1997).  After the first cleavage event, Rb can undergo an 
additional internal cleavage at DSID349 by caspase 3 and 7 (Fattman et al., 2001).  Caspase 
cleavage has been shown to be triggered by stress stimuli such as etoposide  (Karpinich et al., 
2002; Nakajima et al., 1994; Sawada et al., 2000).  Although Rb has been shown to be cleaved by 
caspases under certain conditions (Fattman et al., 2001), the pan-caspase inhibitor Z-VAD-FMK did 
not completely block Rb degradation confirming that additional pathways are involved (Figure 3.4 
A).  Inhibition of phospho-PKC-δ, a downstream target of caspases, by ZVAD confirmed the 
inhibitor was working (Figure 3.4 B).  While caspases may play a role, they are not the only 
pathway involved in degradation of Rb during genotoxic stress.   
 
Rb undergoes Hdm2-mediated degradation in response to genotoxic stress  
Rb interacts with the E3 ligase Hdm2, which targets both Rb and p53 for proteosomal 
degradation and can thereby act as an oncogene when overexpressed (Xiao et al., 1995, Sdek, 
2004).  The critical role Hdm2 plays in maintaining p53 at low cellular levels during normal 
conditions has been established (Momand et al., 1992, Oliner, 1993), but the physiologic 
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significance of the Hdm2-Rb interaction remains less certain.  We hypothesized that Hdm2 may 
mediate the degradation of Rb that occurs in response to p38-mediated phosphorylation.  Indeed, 
degradation of Rb was efficiently inhibited by a small molecule inhibitor of Hdm2 E3 ligase activity 
(Figure 3.5 A).  In co-immunoprecipitation experiments, the physical interaction between Rb and 
Hdm2 was enhanced by etoposide, and by activating endogenous p38 by expression of MKK3, 
but not by activating endogenous Cdks by expression of cyclin D1 (Figure 3.5 B-C).  Specifically, 
Ad-MKK3 treatment increased the interaction between Hdm2 and the hyperphosphorylated form 
of Rb (Figure 3.5 C).  Knock down of Hdm2 using siRNA led to an increase in 
hyperphosphorylation of Rb (Figure 3.6 A) and cells treated with a proteosome inhibitor, MG132, 
resulted in increased levels of phosphorylated Rb (Figure 3.6 B) revealing that baseline 
degradation of Rb occurs in melanoma cells and that hyperphosphorylated forms of Rb were 
being degraded not dephosphorylated.  Taken together, these data suggest that Hdm2 
preferentially interacts with and degrades a phosphorylated form of Rb generated by p38- rather 
than Cdk-mediated phosphorylation, indicating a key mechanistic insight into how the cell cycle 
and apoptosis are regulated through Rb.  
 
Phosphorylation of Rb on Ser567 by p38 induces its degradation by Hdm2 
We speculated that Ser567 may be important in mediating the Rb-Hdm2 interaction.  For all other 
phosphorylation sites on Rb except Ser567, mutation simply blocks phosphorylation.  However, 
we previously showed that Ser567 plays a unique role in maintaining the conformation and 
activity of the pocket (Harbour et al., 1999).  Thus, mutation of Ser567, as in our RbΔ567 
construct, disrupts the pocket structure and function, thereby mimicking the effect of 
phosphorylating this site.  In other words, both phosphorylation of Rb on Ser567 and the RbΔ567 
mutant destabilize and inactivate the Rb protein.  The RbΔ567 mutant interacted strongly with 
Hdm2 in co-immunoprecipitation experiments, whereas wildtype Rb interacted only weakly with 
Hdm2 (Figure 3.7).  Further, RbΔ567 could induce a trimeric complex between Rb, Hdm2 and 
p53, but wildtype Rb could not (Figure 3.7).  The A domain of Rb (Rb-A) was used as a negative 
control because the C-terminus of Rb, which is necessary for Hdm2 binding, is not present in this 
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mutant (Xiao et al., 1995).  These results suggest that p38-mediated phosphorylation of Rb on 
Ser567 regulates Rb protein levels by modulating its interaction with and degradation by Hdm2.   
 
Phosphorylation of Rb on Ser567 by p38 triggers Hdm2-mediated apoptosis   
We wondered whether loss of Hdm2 would inhibit stress-induced apoptosis.   We treated cells 
with a chemical inhibitor of Hdm2 and etoposide and found that the Hdm2 inhibitor inhibited cell 
death (Figure 3.8 A).  Next, we directly targeted p38 and stressed cells with Ad-MKK3.  Once 
again, the Hdm2 inhibitor inhibited apoptosis (Figure 3.8 B).  To confirm these findings we used 
siRNA against Hdm2 and treated cells with etoposide or Ad-MKK3.  Again, apoptosis was 
inhibited (Figure 3.8 C-D).  Taken together, these results suggest that p38-mediated 
phosphorylation of Rb on Ser567 leads to Hdm2-dependent apoptosis.   
 
Phosphorylation of Ser567, but not C-terminal sites, correlates with poor prognosis in 
uveal melanoma patients 
Our lab has demonstrated that Rb phosphorylated on Ser567 is located mostly in the cytoplasm, 
where Rb is inactive and degraded by the proteosome.  In contrast, C-terminal phosphorylated 
Rb is located mostly in the nucleus where it is active (Ma et al., 2003).  Primary human uveal 
melanoma samples were evaluated by immunostaining for phosphorylation of Ser567 and the C-
terminal phosphorylation sites using phospho-specific antibodies.  Consistent with our cell culture 
data, Rb phosphorylated on Ser567 was localized to the cytoplasm, whereas Rb phosphorylated 
on the C-terminal sites Ser807 and Ser811 was located in the nucleus in tumor samples (Figure 
3.9 A).  Ser567 phosphorylation was strongly associated with metastatic death, with all patients 
whose tumor exhibited Ser567 phosphorylation dying of metastasis within five years.  In contrast, 
70% of patients without Ser567 phosphorylation were still alive after ten years (log rank test, P = 
0.0002) (Figure 3.9 B).  On the other hand, phosphorylation of the C-terminal sites Ser807 and 
Ser811 were not associated with metastasis or survival (Figure 3.9 B).  One potential explanation 
for these findings is that Ser567 phosphorylation is an indicator of DNA damage, genomic 
instability and aneuploidy, which we previously showed was a strong predictor of metastatic death 
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(Ehlers and Harbour, 2005).  Consistent with this hypothesis, Ser567 phosphorylation was 
strongly associated with expression of nibrin (Figure 3.9 C), which is a component of the 
MRE11/RAD50 double-strand break repair complex and is up-regulated in tissues with high levels 
of DNA double strand breaks (Wilda et al., 2000).  Taken together, these findings suggest that 
Ser567 phosphorylation is a potential biomarker for aggressive tumors with high degrees of 
aneuploidy. 
 
Ser567 peptide as proof of principle for Rb-directed therapy 
Based on our finding that Ser567 induces apoptosis, at least in part by disrupting the pocket 
structure, we hypothesized that a compound that mimics this disruption of the pocket may allow 
targeted cell death by modulation of Rb.  Such a strategy may be effective in treating cancers that are 
wildtype for Rb.  We reasoned that a peptide containing the region surrounding Ser567 itself may 
compete with and thereby interfere with the interaction of Ser567 with other residues required for 
maintaining the tertiary structure of the pocket.  Thus, we generated a 20 amino acid peptide 
fragment of Rb centered around Ser567, and control peptides in which Ser567 was converted to 
alanine (S567A) or Ser567 and Pro568 were both converted to alanine (S567A/P568A).  To deliver 
these peptides efficiently into the nucleus of cultured cells, the Tat transduction domain was fused to 
the N-terminus of each peptide.  Our lab has previously reported success with this approach (Harbour 
et al., 2002).  Tat-S567 peptide, but not Tat-S567A or Tat-S567A/P568A peptides, efficiently induced 
apoptosis in Mel202 uveal melanoma cells (Figure 3.10 A).  Also, the Tat-S567 peptide, but not Tat-
S567A or Tat-S567A/P568A peptides, efficiently killed U2OS osteosarcoma cells (Figure 3.10 B).  
Additionally, the Tat-S567 peptide activated an E2F-dependent promoter-reporter more than Tat 
alone (Figure 3.10 C).  Further work is needed to explore the precise mechanism by which the 
Ser567 peptide functions, but these findings provide promise for modulating Rb as an approach to 
targeted therapy.   
 
3.5 Discussion  
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Genotoxic stress or direct activation of endogenous p38 using Ad-MKK3 results in degradation of 
Rb.  Degradation occurs during stress-induced apoptosis but not during the cell cycle, thus 
indicating an important mechanistic insight into how these two processes are differentially 
regulated through Rb.  This degradation in response to etoposide occurred in melanoma cells 
and primary melanocytes, as well as A375 cutaneous melanoma, 10T/2 mouse fibroblasts, 92.1 
uveal melanoma, and MCF-7 and MB-MDA-231 breast cancer cells indicating this response is not 
limited to the melanocyte lineage.  Although Rb has been shown to be cleaved by caspases 
under certain conditions (Fattman et al., 1997; Fattman et al., 2001), we found that the pan-
caspase inhibitor Z-VAD-FMK could not block etoposide-induced Rb degradation.  This is 
consistent with data demonstrating that fibroblasts from mice expressing the Rb D886A mutant, 
which blocks caspase cleavage of Rb, still undergo Rb degradation and apoptosis (Tan et al., 
1997).  Studies have shown that Rb can interact with the E3 ligase Hdm2, which targets proteins 
such as Rb and p53 for proteosomal degradation, such that it can act as an oncogene when 
overexpressed (Sdek et al., 2005; Sdek et al., 2004; Xiao et al., 1995).   
 
There is some debate in the field as to whether Hdm2 binds the hypophosphorylated or 
hyperphosphorylated Rb and whether or not Hdm2 ubiquitinates Rb, but there is a consensus 
that Rb can undergo Hdm2- and proteosomal-dependent degradation.  Sdek et al claim that 
Hdm2 preferentially interacts with hypophosphorylated Rb.  However, their immunoprecipitations 
involve a GST-Rb fusion protein expressed in U2OS cells.  We argue that our more physiological 
system of using endogenous Rb, while resulting in contradictory data, is more relevant (Sdek et 
al., 2004). This group agrees that the Hdm2-mediated degradation of Rb is dependent on the 
proteosome, but argues it is ubiquitin-independent (Sdek et al., 2005).  However, their data 
demonstrating that the ligase-inactive Hdm2 RING finger mutant, in which cysteine464 is mutated 
to an alanine, abolishes degradation of Rb argues against their conclusion that this mechanism is 
independent of ubiquitination.  The RING finger motif, consisting of cysteine and histidines which 
interact with two zinc ions, is important for ubiquitination activity (Fang et al., 2000; Itahana et al., 
2007).  Further, other groups have found that Hdm2 does, indeed, ubiquitinate Rb in an 
  
100 
 
overexpression setting and an endogenous setting (Uchida et al., 2005; von Willebrand et al., 
2003).   
 
While several groups have looked at the Rb-Hdm2 interaction, the phosphorylation sites and 
mechanism were previously unknown.  We shed light on the mechanism behind the Rb-Hdm2 
interaction by revealing that phosphorylation of Rb on Ser567 enhances the Rb-Hdm2 interaction.  
von Willebrand et al mutated 11 of the 16 possible phosphorylation sites and found that Rb was 
still ubiquitinated.  Interestingly, the only sites they did not mutate were Ser567 and 4 sites in the 
N-terminus, supporting our findings that Ser567 plays a role in the ubiquitination and degradation 
of Rb (von Willebrand et al., 2003).   
 
Not only does phosphorylation of Ser567 lead to an interaction between Rb and Hdm2, but it also 
leads to an Rb-p53 interaction.  We confirm that a trimeric complex can be formed between 
Hdm2, Rb, and p53 in our system (Hsieh et al., 1999; Hsieh et al., 2002; Yap et al., 1999).  Our 
data provide a mechanistic explanation for how Hdm2, an oncogene, links the two most 
prominent tumor suppressors.  This interaction between Rb and Hdm2 and p53 represents a rare 
circumstance in which phosphorylation of Rb enhances, rather than abolishes, its interaction with 
binding partners.   
 
Our cell culture findings are supported by work on human tissue demonstrating that Ser567 is a 
marker for high levels of stress in uveal melanoma patients.  Our lab has performed gene 
expression profiling on uveal melanomas and found that the tumors can be divided into two 
classes which determine the likelihood of survival.  Class 1 tumors have a spindle morphology 
and almost never metastasize (low grade).  Class 2 tumors have an epithelioid morphology, and 
a high probably of metastasis and death (high grade) (Onken et al., 2004).  We have found that 
phospho-Rb-Ser567 positive staining correlates with class 2 patients, while class 1 patients were 
negative for Ser567 phosphorylation.  This information could be valuable in Rb-targeted cancer 
therapy.  As proof of principle, our lab created short peptides of the amino acids surrounding 
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Ser567.  Preliminary experiments revealed that the Ser567 peptide kills cancer cells.  Taken 
together we have demonstrated that Ser567 phosphorylation promotes Hdm2-mediated 
degradation of Rb ultimately resulting in cell death, is a predictor of metastatic death in uveal 
melanoma, and is a potential target for therapeutic applications.   
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3.6 Figures  
 
 
 
 
 
 
Figure 3.1 Genotoxic stress leads to degradation of Rb in melanoma cells and 
melanocytes   
(A) Mel202 cells were treated with 12.5 µM etoposide for 0, 24, 48, 72 h and immunoblotted for 
Rb.  (B) Primary human uveal melanocytes were treated with 0, 1.5, 3, 6, 12.5, 25, 50 µM 
etoposide for 48 h and immunoblotted for Rb.  (C) 92.1 uveal melanoma cells were treated with 6 
or 12.5 µM etoposide for 48 h and immunoblotted for Rb.  (D) A375 cutaneous melanoma cells 
were treated with 0, 1.5, 6, 12.5 µM of etoposide for 48 h and immunoblotted for Rb.   
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Figure 3.2 Genotoxic stress leads to degradation of Rb in other cell types 
(A) U2OS osteosarcoma cells were treated with 0, 1.5, 3, 6, 12.5, 25 µM of etoposide for 48 h 
and immunoblotted for Rb.  (B) 10T/2 mouse fibroblasts were treated with 1.5 or 3 µM of 
etoposide for 48 h and immunoblotted for Rb.  (C) MCF-7 cells were treated with 0, 0.7, 1.5, 6, 
12.5, 25 µM of etoposide for 48 h and immunoblotted for Rb.  (D) MDA-MB-123 cells were treated 
with 0, 0.7, 1.5, 6, 12.5, 25, 50 µM of etoposide for 48 h and immunoblotted for Rb. 
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Figure 3.3 Activation of p38 leads to degradation of Rb 
Mel202 cells were treated with Ad-GFP, Ad-cycD1, or Ad-MKK3 at an MOI of 30 for 48 h and 
immunoblotted for total Rb, phospho-p38, or cyclin D1.   
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Figure 3.4 Caspase inhibition fails to block etoposide induced phosphorylation of Rb   
(A) ZVAD-FMK and etoposide were used at 50 µM and 12.5 µM respectively for 72 h.  Lysates 
were immunoblotted for Rb.  (B) Control demonstrating ZVAD-FMK is active.  50 µM of ZVAD-
FMK inhibited phospho-PKC-δ, a downstream caspase target. 
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Figure 3.5 Phosphorylation of Rb by p38 enhances the Rb-Hdm2 interaction 
(A)  Mel202 cells were treated for 48 h with or without 12.5 µM of etoposide.  50 µM of Hdm2 
inhibitor was used in lane 2, 5 µM in lane 4, and 10 µM in lane 6.  No Hdm2 inhibitor was used in 
Lanes 1 and 3.  (B) Mel202 cells were treated with 12.5 µM etoposide for 48 h.  
Immunoprecipitation for endogenous Hdm2 was performed and samples were immunoblotted for 
endogenous Rb.  Total lysates were immunoblotted for Rb and Hdm2.  (C) Mel202 cells were 
treated with Ad-cycD1 or Ad-MKK3 at an MOI of 15 for 48 h, immunoprecipitated for endogenous 
Hdm2, and immunoblotted for endogenous total Rb.  Total lysates were immunoblotted for Rb, 
phospho-p38, and Hdm2.   
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Figure 3.6 Rb is ubiquitinated and degraded in the proteosome 
(A) Mel202 cells were treated with 50 nM of scrambled or Hdm2 siRNA for 72 h and 
immunoblotted for Rb or Hdm2.  (B) Mel202 cells were treated with 50 µM of MG132 for 3 h and 
immunoblotted for Rb.   
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Figure 3.7 Phosphorylation of Rb on Ser567 by p38 enhances the Rb-Hdm2 interaction 
Mel202 cells were transfected with Gal4-tagged Rb constructs: Rb-A (the A domain of Rb serves 
as a negative control), Rb, Rb∆567, or Rb∆568.  Cells were immunoprecipitated for Gal4 to pull 
down Rb, and immunoblotted for endogenous Hdm2 and endogenous p53.  Total lysates were 
immunoblotted for Hdm2, p53, and Gal4.   
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Figure 3.8 Stress-induced apoptosis is mediated by Hdm2 
(A) Mel202 cells were treated with 10 µM Hdm2 inhibitor and 12.5 µM etoposide for 48 h and 
TUNEL staining was performed.  (B) Mel202 cells were treated with 10 µM Hdm2 inhibitor for 72 
h.  Cells were treated Ad-LacZ or Ad-MKK3 at a MOI of 100 for 48 h and TUNEL staining was 
performed.  (C) Mel202 cells were transfected with Hdm2 siRNA for 72 h and treated with 12.5 
µM etoposide for 48 h and TUNEL staining was performed.  (D) Mel202 cells were transfected 
with Hdm2 siRNA for 72 h and treated with Ad-LacZ or Ad-MKK3 at an MOI of 50 for 48 h and 
TUNEL staining was performed.   
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Figure 3.9 Phosphorylation of Ser567, but not C-terminal sites, correlates with poor 
prognosis in uveal melanoma patients 
(A) IHC was performed on formalin-fixed, paraffin-embedded tissue sections on primary human 
uveal melanomas and stained for Rb-phospho-Ser567 or Rb-phospho-807-811.  Arrow points to 
a cell staining positive for Rb-phospho-Ser567 in the cytoplasm or a cell staining positive for Rb-
phospho-807-811 in the nucleus and mitotic bodies.  (B) Kaplan Meier analysis reveals that 
patients with positive Rb-phospho-Ser567 staining have a worse prognosis than patients with 
negative staining while Rb-phospho-807-811 staining does not correlate with patient outcome.  
(C) Ser567 phosphorylation is associated with nibrin expression.  
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Figure 3.10 Ser567 peptide as proof of principle for Rb-directed therapy 
(A)  Tat-S567, Tat-S567A or Tat-S567A/P568A peptides were added to Mel202 cells and cell 
viability assays were performed 24 h later.  (B) Tat-S567, Tat-S567A or Tat-S567A/P568A 
peptides were added to U2OS osteosarcoma cells and cell viability assays were performed 24 h 
later.  (C) Tat alone or Tat-S567 peptides were used in a luciferase assay with the E2F-
dependent cyclin E promoter.  Cells were transfected with CMV empty vector or E2F1 expression 
construct.  (M. Onken and L. Worley unpublished data) 
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4.1 Discussion  
Rb functions as a tumor suppressor by inhibiting cell division (Goodrich et al., 1991; Knudsen et 
al., 1998).  In order for cells to divide, Rb is temporarily phosphorylated by Cdks, at up to 16 
Ser/Thr-Pro phospho-acceptor sites, thereby allowing cells to traverse from G1 into S phase 
(Chen et al., 1989; Hinds et al., 1992; Lin et al., 1991; Lundberg and Weinberg, 1998; Serrano et 
al., 1993).  Most tumors co-opt this mechanism and maintain Rb in a partially 
hyperphosphorylated state, often by constitutive activation of cyclin-Cdks such as cyclin D1 or 
inactivation of Cdk inhibitors such as p16
Ink4a
, allowing for continual cell cycle progression (Sherr 
and McCormick, 2002).   
These findings are reflected in the prevailing view of Rb function as an ‗on-off‘ regulator of the 
G1/S transition in which Rb is completely inactivated every cell cycle by Cdks, releasing E2Fs to 
activate cell cycle genes.  Though widely accepted in the Rb field, this traditional model is 
inadequate to account for many basic observations. The simple fact that cells do not undergo 
apoptosis with every attempt at cell division implies that Rb is not completely inactivated with 
every cell cycle as this would result E2F-mediated transcription of pro-apoptotic genes (Ginsberg, 
2002; Zhao et al., 2005).  The strikingly different phenotypes associated with complete Rb 
inactivation (by genetic deletion or excessive hyperphosphorylation) and partial Rb inhibition (by 
loss of p16
Ink4a 
or overexpression of cyclin D) indicate that these proteins do not constitute a 
simple linear pathway, as previously envisaged (Figure 4.1) (Sherr, 2000). 
We hypothesized that Rb is only partially phosphorylated and inhibited during normal cell division, 
and this incomplete inactivation is sufficient to block its cell cycle inhibitory function and to allow 
cell cycle progression without triggering apoptosis.  The residual anti-apoptotic activity persists 
unless Rb is more completely phosphorylated (or if RB is deleted), suggesting that Rb may serve 
as a buffer against apoptosis during normal cell division and a checkpoint for triggering apoptosis 
under abnormal stress conditions such as excessive DNA damage in which apoptosis may be 
favored over proliferation or differentiation.   
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In order to test this hypothesis and explore why these mechanisms for inactivating Rb that have 
been assumed to be functionally equivalent result in such strikingly different phenotypic 
outcomes, we developed an experimental model system in which Rb degradation and apoptosis 
were induced by genotoxic stress in Mel202 uveal melanoma cells, which have been extensively 
characterized and shown to be wildtype for Rb and p53 (Sun et al., 2005).  Uveal melanoma is 
the most common type of eye tumor with roughly half of the cases resulting in death due to liver 
metastasis (Harbour, 2006).  Rb is necessary for melanocyte survival making it an attractive 
model to study Rb (Macleod et al., 1996; Yu et al., 2003).  Several key experiments were 
confirmed using primary melanocytes or other cell lines, demonstrating our findings were not 
specific to Mel202 cells.  We used etoposide, a DNA damaging reagent that causes double-
stranded breaks to induce genotoxic stress.  Our findings were confirmed using adenovirus 
expressing MKK3, a direct activator of p38, to induce stress. 
 
We propose a new model, based on our hypothesis, in which Rb exists not only in fully active and 
fully inactive forms, but rather, in multiple phosphorylation states that have differing abilities to 
bind E2Fs and other proteins, and to inhibit cell division and apoptosis (Ianari et al., 2009; 
Lundberg and Weinberg, 1998; Ma et al., 2003).  Evidence for this new model has been 
demonstrated. Partially phosphorylated forms of Rb bind E2Fs (Ezhevsky et al., 2001; Ezhevsky 
et al., 1997), and Rb continues to co-localize with E2Fs at certain promoters in vivo beyond the 
G1/S transition despite being sufficiently phosphorylated to allow for cell cycle progression (Wells 
et al., 2000; Wells et al., 2003).  Phosphorylation of Rb by Cdks during cell division does not lead 
to Rb degradation or apoptosis.  This normal cycling depends on Rb remaining in a reversible, 
partially inactivated state such that it can still repress pro-apoptotic E2Fs (Wells et al., 2003; 
Young et al., 2003).  The different phosphorylated forms of Rb appear to allow the cell to 
differentially control cell cycle genes and apoptotic genes, the former being derepressed by 
partial phosphorylation of Rb and the latter being activated by more complete phosphorylation of 
Rb (Young and Longmore, 2004a; Young et al., 2003; Zhang et al., 2000).  The anti-proliferative 
and anti-apoptotic functions of Rb can be biochemically uncoupled and are both mediated largely 
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through interactions with E2Fs (Chau et al., 2006).  Taken together, these observations indicate 
that the decision between proliferation and apoptosis is made, at least in part, by the manner in 
which Rb is phosphorylated.  
 
These findings raise a key question: if Cdks do not completely phosphorylate nor fully inactivate 
Rb during the normal cell cycle, then under what physiologic conditions and by what mechanism 
does complete inactivation of Rb and concomitant activation of apoptotic genes occur?  In recent 
years, other kinases capable of phosphorylating Rb have been identified, such as p38, which is 
activated during cellular stress and promotes apoptosis (Hou et al., 2002; Nath et al., 2003; Wang 
et al., 1999).  p38 has been shown to phosphorylate Rb in response to stress and death receptor 
signaling in multiple cell types, such as endothelial cells, cerebellar neurons, Jurkat lymphocytic 
cells, colon cancer cells, and melanoma cells (Hou et al., 2002; Kishore et al., 2003; Lee et al., 
2003; Nath et al., 2003; Wang et al., 1999; Yeste-Velasco et al., 2009).  Rather than promoting 
cell division, phosphorylation of Rb by p38 appears to promote apoptosis under physiologic 
conditions of cellular stress (Bowen et al., 2002).  While the ability of p38 to phosphorylate Rb 
has been established, it remains unclear why p38 favors apoptosis whereas Cdks promote cell 
division.  One possibility is that p38 preferentially phosphorylates a different site or sites on Rb 
that confer different biochemical and, thus, physiologic effects.  
 
Several lines of evidence point to the Ser567 phosphoacceptor site as playing an important role 
in Rb regulation.  The Ser567-Pro568 motif is highly conserved across species (Ma et al., 2003), 
suggesting that it is the ability of Ser567 to be phosphorylated that is important in its function.  
Ser567 is the only phosphorylation site on Rb that is a target of naturally occurring mutations in 
human retinoblastoma (Templeton et al., 1991; Yilmaz et al., 1998), revealing that it plays a 
different role than the other 15 phosphorylation sites.  Phosphorylation of this site Ser567 has not 
been reported to be phosphorylated during normal cell cycle progression (Lees et al., 1991).  
Ser567 is the only phosphorylation site on Rb that, when phosphorylated or mutated, disrupts the 
A-B box interaction, destabilizes the pocket structure, and abrogates interaction with E2Fs 
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(Harbour et al., 1999; Ma et al., 2003).  Crystallographic studies have shown that Ser567 
mediates critical contacts between the A and B boxes, and that phosphorylation of this site would 
be predicted to destabilize the pocket structure and eliminate the E2F binding site (Lee et al., 
2002; Lee et al., 1998).  Because Ser567 is buried in the pocket domain, rather than being 
exposed such as C-terminal residues, it is the least efficiently phosphorylated site by Cdks 
(Harbour et al., 1999).  Phosphorylation of Ser567 by Cdks requires prior phosphorylation of the 
C-terminus, which contains Cdk docking sites that bring cyclin-Cdk complexes into proximity of 
Ser567 through an intramolecular interaction between the C-terminus and the pocket (Harbour et 
al., 1999).  We demonstrate that p38 efficiently phosphorylates Ser567 under conditions favoring 
apoptosis, and this phosphorylation does not depend on the intramolecular interactions and 
conformational changes associated with Cdk-mediated phosphorylation.  This would allow p38 to 
bypass the Cdks and directly regulate Rb in a cell cycle-independent manner during apoptotic 
signaling.  The ability of p38 to phosphorylate Ser567 may be due to its small size, allowing it to 
access Ser567, which is located in a recess at the interface of the A and B boxes of the pocket, 
where it would likely be inaccessible to the much larger cyclin-Cdk complexes under normal 
circumstances (Harbour et al., 1999; Lee et al., 2002).  Importantly, inhibition of Ser567 
phosphorylation, but not of Ser780 a C-terminal site phosphorylated during the cell cycle, 
inhibited etoposide-induced apoptosis.  Taken together, these findings suggest that p38 
phosphorylates Rb in a cell cycle-independent manner and that it is the ability of p38 to 
phosphorylate Ser567 efficiently that distinguishes the pro-apoptotic effect of p38 phosphorylation 
from the proliferative effect of Cdk phosphorylation.  Consistent with this hypothesis, Nath and 
colleagues showed that an Rb mutant with all available phosphorylation sites mutated to prevent 
their phosphorylation except Ser567 was unable to rescue p38-mediated inactivation of Rb (Nath 
et al., 2003).   Similarly, von Willebrand and colleagues showed that a phosphorylation defective 
Rb mutant was not resistant to ubiquitination despite elimination of most of the phosphorylation 
sites; Ser567 was one of the few sites that were not mutated (von Willebrand et al., 2003).  The 
ability of p38, but not Cdks, to phosphorylate Rb on Ser567 efficiently may provide a key to 
understanding the different effect that p38 has on Rb compared to Cdks. 
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In order to further characterize the mechanism of Rb-mediated apoptosis in response to 
genotoxic stress we investigated the roles of both E2F1 and p53—two transcription factors 
intricately linked to Rb.  Stress led to release of E2F1 confirming our hypothesis that while Rb is 
only partially phosphorylated and still bound to E2F1 during the cell cycle, a more complete 
phosphorylation by Ser567 results loss of the Rb-E2F interaction, allowing for transcription of pro-
apoptotic genes.  Reduction in p53 or E2F1 levels inhibited stress-mediated apoptosis 
corroborating with data demonstrating that etoposide activates p53 (Lowe et al., 1993), activates 
E2F1 (Ginsberg, 2002), and causes E2F1 to favor pro-apoptotic target genes such as p73 rather 
than cell cycle target genes (Pediconi et al., 2003).  
 
We demonstrate that phosphorylation of Rb on Ser567 enhances its interaction with Hdm2, an 
oncogene that is overexpressed in many human tumors including uveal and cutaneous 
melanoma (Brantley and Harbour, 2000; Polsky et al., 2002; Polsky et al., 2001).  Herein, we 
provide new insights into the relationship between Hdm2, an E3 ligase and oncoprotein, and the 
tumor suppressors p53 and Rb.  Our finding that genotoxic stress promotes interaction between 
Rb and Hdm2 parallels recent findings that a p53 activating compound promotes Mdm2-mediated 
degradation of p21
Cip1
, both ultimately leading to cell death (Enge et al., 2009).  It has long been 
known that Hdm2 interacts with and triggers the degradation of both p53 and Rb (Momand et al., 
1992; Sdek et al., 2005; Uchida et al., 2005; von Willebrand et al., 2003; Xiao et al., 1995).  In 
particular, Hdm2 binds and ubiquitinates Rb, targeting it for degradation (Sdek et al., 2004; von 
Willebrand et al., 2003; Xiao et al., 1995).  We show that phosphorylation of Ser567 and 
consequent disruption of the Rb pocket may be a critical event that triggers interaction of Rb with 
Hdm2.  This represents a rare circumstance in which phosphorylation of Rb enhances, rather 
than abolishes, its interaction with a binding partner.   Further, it is tempting to speculate that the 
dual role of Hdm2 in regulating protein levels of two major tumor suppressors – Rb and p53 – is 
physiologically relevant, but this has not been confirmed experimentally.  In this model, (Figure 
4.2) during quiescence, Rb is hypophosphorylated and active, preventing cell cycle progression.  
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In parallel, Hdm2 maintains p53 at low levels by proteosomal degradation.  In normal cycling 
cells, Rb is phosphorylated and partially inactivated by Cdks, and Hdm2 continues to maintain 
p53 at low levels.  During low levels of stress cycle arrest would be favored through disruption of 
the Hdm2-p53 interaction and subsequent accumulation of activated p53.  But under these 
conditions, p38 would not phosphorylate Rb, and Hdm2 would thus not interact with Rb.  The 
result would be active Rb that could cooperate with p53 to trigger cell cycle arrest.  At higher 
stress levels, apoptosis would be favored as a mechanism for eliminating a potentially deleterious 
cell.  Disruption of the Hdm2-p53 interaction would activate p53, and release Hdm2; however, in 
this setting, activated p38 would phosphorylate Rb on Ser567, allowing Hdm2 to interact with Rb 
triggering its degradation.  Furthermore, it has been shown that Rb-Hdm2 binding stabilizes p53 
and promotes p53-dependent apoptosis (Hsieh et al., 1999; Yap et al., 1999).  MK2, a direct 
transcriptional target of p38, phosphorylates Hdm2 and enhances its activity (Weber et al., 2005), 
thus p38 may promote the degradation of Rb through multiple complementary mechanisms.  Loss 
of Rb and the consequent release of pro-apoptotic E2Fs, coupled with activation of p53, then tips 
the balance of cellular events in favor of apoptosis over cell cycle arrest (Sun et al., 2010).  
Without such a mechanism, activation of p53 might indiscriminately trigger both cell cycle arrest 
and apoptotic programs, leading to a chaotic and inefficient response to stress.  Consistent with 
this model, p53 and Rb compete for binding to Hdm2 (Uchida et al., 2005), p53 requires Rb for 
efficient induction of cell cycle arrest (Harrington et al., 1998), and activation of p53 triggers 
apoptosis in the absence of Rb (Macleod et al., 1996).   
  
There are ongoing efforts to target p38 in a clinical setting in a wide range of diseases and 
therefore insights gleaned from this work could provide new therapeutic insights.  Stimulating or 
mimicking p38 signaling to Rb promotes cancer cell death and sensitizes cancer cells to therapy.   
Compounds that preferentially activate MKK3 and/or p38α in Rb positive cancer cells versus 
normal cells  such as anisomycin (an antibiotic produced by Streptomyces griseolus)  (Mauro et 
al., 2002) or Resveratrol (found in red wine and grapes) (Bai et al. 2010), may sensitize cells to 
chemotherapy and radiation therapy (Olson and Hallahan, 2004).  There is evidence that the p38 
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pathway plays a critical role not only in tumorigenesis, but also in metastasis (Horak et al., 2008).  
MKK4, 6, and 7, direct activators of p38, have been shown to inhibit metastasis by promoting 
tumor cell dormancy.  p38 activators may provide therapy against metastasis as well as 
tumorigenesis.   
On the other hand, compounds that inhibit p38 are also currently being researched and are in 
clinical trials.  Rb hyperphosphorylation and degradation mediates neuronal cell death in multiple 
neurodegenerative disorders such as Parkinson‘s disease, Alzheimer‘s disease and stroke 
(Giovanni et al, 2000; Hayashi et al, 2000; Hoglinger et al, 2007; Liu & Greene, 2001; O'Hare et 
al, 2000; Park et al, 2000; Ramalho et al, 2004; Thakur et al, 2008).  Further, p38 can regulate Rb 
and modulate cell death in neurons, and pharmacologic blockade of p38 has a neuroprotection 
effect (Hou et al, 2002; Yeste-Velasco et al, 2009).  Similar mechanisms may govern the 
development of atherosclerosis and cardiomyocyte apoptosis that occur in association with 
myocardial infarction (Hauck et al, 2002; Proctor et al, 2008).  p38 is upregulated in inflammatory 
diseases such as rheumatoid arthritis (RA) and BIB796 (Boeringer Ingelheim Pharmaceuticals, 
Inc., Ridgefield, CT, USA), which prevents ATP binding, and is in stage III trials for treating RA 
(Cuadrado and Nebreda, 2010; Pargellis et al., 2002).  In some cases p38 promotes cell 
migration and implantation in cancer and therefore inhibiting p38, rather than activating p38 as 
previously discussed, would be valuable.  For example, ARRY-797 (Biopharma, Rockville, MD, 
USA) is in phase II trials to treat cytokine driven cancers in combination with cisplatin and SCIO-
469 (Scios Inc, Johnson and Johnson, New Brunswick, NJ, USA) is in phase II to treat multiple 
myeloma (Coulthard et al., 2009).   
 
Although there are over a dozen p38 inhibitors currently in clinical trials many are causing 
adverse effects such as liver toxicity.  New ways of inhibiting p38 are being developed in order to 
thwart this problem.  One method of avoiding toxicity is to use a drug delivery system that allows 
for low levels of the inhibitors to be maintained in specific organs as has been recently shown for 
cardiac dysfunction (Cuadrado and Nebreda 2010).  Another method that was recently published 
is the use of a fusion peptide with a p38 docking sequence and Tat transmembrane sequence 
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which has been shown to be anti-inflammatory in mice (Fu et al., 2008a).  A third approach is to 
instead target downstream effectors of p38 such as the pro-inflammatory MAPKAPK2 (Coulthard 
et al., 2009). 
 
In this study, we provide evidence for a pro-apoptotic signaling pathway induced by genotoxic 
stress, in which p38 phosphorylates Rb in a manner that triggers E2F1-, p53-, and Hdm2-
mediated cell death.  The Rb residue Ser567 is implicated as a key target of this p38-mediated 
phosphorylation, providing a molecular explanation for why Rb phosphorylation by p38 differs 
mechanistically and physiologically from that catalyzed by Cdks.  This p38-mediated pathway 
could provide a rapid, cell cycle-independent means for overriding the cell cycle and triggering 
apoptosis in response to genotoxic stress.  These findings may provide new insights for 
therapeutic intervention, both to inhibit cell death in degenerative diseases and to promote cell 
death in cancer where manipulation of this mechanism could kill cells directly or sensitize them to 
radiation or chemotherapy.  
 
4.2 Future directions 
Determine if other E2F family members play a role in our experimental model 
Our studies determined that phosphorylation of Rb on Ser567 led to derepression of E2F1.  E2F1 
was investigated because it is the main E2F member involved in apoptosis and is required for 
p53-depedent apoptosis.  Loss of E2F1 causes a massive reduction in apoptosis and 
overexpression of E2F1 increases apoptosis (Pan et al., 1998; Stevaux and Dyson, 2002).  
Interestingly, Rb has a separate binding site contained in the C-terminus, rather than spanning 
the pocket domain and C-terminus, that only binds the E2F1 family member.  E2F1 levels are 
increased during etoposide treatment and the binding to Rb on this separate site is lost (Dick and 
Dyson, 2003).  Future work will be necessary to determine if other E2F family members play a 
role.   
 
Determine if other stress kinases phosphorylate Rb on Ser567 
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We chose to focus on p38 because there are many lines of evidence revealing that p38 
phosphorylates Rb during stress.  While it was not known that p38 phosphorylates Rb in our 
system, p38 had been shown to phosphorylate Rb in several other cell types (Hou et al., 2002; 
Kishore et al., 2003; Lee et al., 2003; Nath et al., 2003; Wang et al., 1999; Yeste-Velasco et al., 
2009).  However, this mechanism is not mutually exclusive with other strategies that the cell may 
employ for differentially regulating cell proliferation and apoptosis, such as through PI3K/Akt 
signaling to block the E2F1 apoptotic program during proliferation (Dick and Dyson, 2003; 
Hallstrom et al., 2008; Hallstrom and Nevins, 2003) or through ATM which has been shown to 
affect Rb phosphorylation levels (Pizarro et al. 2010).  Other MAPK members such as ERK1/2 or 
JNK could also be tested (Bowen et al., 2002; Chauhan et al., 1999; Wang et al., 1999).  
Additional stress kinases could work in concert with p38 to promote Rb degradation and 
apoptosis.  It would be interesting to examine if these kinases phosphorylate Rb directly on 
Ser567 in a cell cycle-independent manner as p38 does.  
 
An unbiased approach to identify kinases that phosphorylate Rb during stress could be employed 
by using a serine/threonine kinase array (Invitrogen Protoarray, Carlsbad, CA) (Jones et al., 
2006).  In vitro kinase assays would be performed to validate array results.  Investigating other 
kinases that phosphorylate Ser567 will allow for additional therapeutic targets.   
 
Unbiased approach to look at differential phosphorylation 
We specifically looked at Ser567 for a number of reasons; it is not phosphorylated during the 
normal cell cycle, it is a target of missense mutations in tumors, and it is located at a unique 
location at the interface of the A and B boxes in the pocket domain (Lee et al., 2002; Lee et al., 
1998; Templeton et al., 1991; Yilmaz et al., 1998).  However, there are 15 other phosphoacceptor 
sites on Rb.  An unbiased approach to look at all 16 phosphorylation sites in both a cell cycle 
setting and a stress setting would be an interesting future experiment.  We performed preliminary 
mass spectrometry experiments in collaboration with Reid Townsend and obtained excellent 
coverage of the Rb protein, but unfortunately we were not able to obtain phosphorylated Rb 
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fragments.  Further troubleshooting will need to be done in order to obtain Rb phospho-peptides 
by mass spectrometry.   
 
An unbiased approach to determine how differential phosphorylation of Rb by Cdks 
versus p38 regulates its interaction with E2Fs and its occupation of cell cycle versus 
apoptotic gene promoters 
ChIP-chip or chIP-sequencing (chIP-seq) could be performed as an unbiased approach to look at 
what promoters Rb is bound to during cell cycle conditions versus apoptotic conditions.  Previous 
experiments have investigated Rb promoter occupation by chIP, but none to date have 
addressed this question.  The Farnham lab performed chIP experiments on Rb during different 
stages of the cell cycle (Wells et al., 2000).  Other groups have looked at Rb on specific 
promoters after stress, for example, in doxorubicin treated MCF-7 breast cancer cells and T98G 
glioblastoma cells (Ianari et al., 2009; Jackson and Pereira-Smith, 2006) or by TNF-α stimulation 
in Ramos Burkitt's lymphoma cells (Dasgupta et al., 2004), but all of these studies looked at only 
a handful of promoters, rather than using a promoter array. 
 
Several groups have used chIP-chip or chIP-seq in order to look at Rb promoter occupation in an 
unbiased manner.  ChIP-chip experiments have been performed on Rb in G0 or S phase arrested 
cells (Wells et al., 2003) and on E1A treated fibroblasts (Young and Longmore, 2004b).  The 
newly developed chIP-seq has been used to investigate the role of the pocket protein family in 
quiescence and senescence in fibroblasts (Chicas et al. 2010).  While these studies added 
valuable knowledge to the Rb field none of them address how differential phosphorylation may 
regulate Rb promoter occupation. We performed chIP experiments for Rb in cells that were 
treated with etoposide or untreated and looking at E2F targets such as TP53 and APAF1.  We 
found that TP53 and APAF1 were bound to Rb in untreated cells but not in treated cells.  The 
samples were sent to NimbleGen (HG18 RefSeq Promoter C4226-00-01), but unfortunately the 
experimental samples were not enriched compared to the input and no data was obtained.  
Further troubleshooting will need to be performed in order to complete this experiment.   
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Look at the role of Ser567 phosphorylation in other cancers  
We investigated the role of Rb hyperphosphorylation in patient prognosis.  A phospho-Rb-567 
specific antibody was used in IHC on uveal melanoma samples from Dr. Harbour‘s patients and 
Ser567 phosphorylation correlated with patient outcome.  Phosphorylation at this site may be an 
indicator of severely stressed and abnormal cells in other cancers as well.    
 
Investigate the Role of the p38-Rb pathway in vivo 
p38α floxed mice (Engel et al., 2005) could be crossed with Tyrosinase-Cre mice (Tonks et al., 
2005; Tonks et al., 2003) in order to obtain conditional knockout (CKO) mice with p38α 
specifically knocked out in melanocytes.  Tyrosinase is an enzyme involved in the early stages of 
melanogenesis (Pawelek et al., 1980).  A p38α conditional mouse would be used because the 
p38α knockout is embryonic lethal at day E10.5 due to vascularization defects (Adams et al., 
2000; Allen et al., 2000; Mudgett et al., 2000; Tamura et al., 2000).  First, the phenotype of these 
mice would be assessed as these mice have never been crossed before.  Rb phosphorylation 
status, amount of death, and amount of proliferation could be examined. Additionally, the initiating 
agent 7,12-dimethyl-benz[a]anthracene (DMBA) followed by the promoting agent the phorbol 
myristate acetate (PMA) could be administered to the skin of the mice to induce melanoma 
formation (Abel et al., 2009; Broome Powell et al., 1999).  Differences in Rb phosphorylation 
status, apoptosis, proliferation, and tumor burden would be investigated.  We would predict that 
loss of p38α would result in a loss of ability to remove melanocytes exposed to carcinogenic DNA 
damage.  Loss of p38α may accelerate tumor progression through more rapid accumulation of 
DNA damage and genomic instability.  Consistent with this hypothesis, p38α loss has been 
shown to induce cardiomyocyte proliferation in vivo (Engel et al., 2005).     
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4.3 Figures 
 
 
 
 
 
 
 
 
 
 
4.1 Rb is inactivated by several mechanisms 
Rb plays a role in melanocyte differentiation, proliferation, and apoptosis. In melanocytes, Mitf 
stimulates Rb hypophosphorylation through activation of p16
Ink4a
, which couples cell cycle exit 
with differentiation. Rb is also necessary to maintain a differentiated state, since partial 
phosphorylation of Rb by loss of p16
Ink4a
 or overexpression of cyclin D causes melanocytes to re-
enter the cell cycle. Complete inactivation of Rb through genetic mutations or through excessive 
phosphorylation (e.g., Ser567 phosphorylation) leads to high levels of free E2F and favors 
apoptosis over proliferation. Adapted from (Delston and Harbour, 2006). 
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Figure 4.2 Hypothesis for how p38-mediated phosphorylation of Rb on Ser567 provides a 
death signal, rather than the Cdk-mediated proliferative signal, and how shuttling of Hdm2 
between p53 and Rb may tightly regulate the cellular response to stress    
In quiescent cells, Rb is hypophosphorylated and active, preventing cell cycle progression.  In 
parallel, Hdm2 maintains p53 at low levels by proteosomal degradation.  In normal cycling cells, 
Rb is phosphorylated and partially inactivated by Cdks, and Hdm2 continues to maintain p53 at 
low levels.  When cells are exposed to low levels of genotoxic and perhaps other forms of stress, 
p53 is phosphorylated and released from Hdm2, allowing cellular levels of p53 to increase.  A 
major effect of this increase in p53 is transactivation of p21
Cip1
 which, in turn, promotes 
hypophosphorylation and activation of Rb.  Rb is available because it has not been degraded by 
activation of p38.  The net result is stress-induced cell cycle arrest.  When cells are exposed to 
higher levels of stress, p53 accumulates and, in addition, p38 is activated to phosphorylate Rb on 
Ser567, which promotes interaction with Hdm2, degradation of Rb, and E2F1-mediated 
apoptosis.   With Rb degraded and unavailable to cooperate with p53 to induce cell cycle arrest, 
the apoptotic genes under basal inhibition by Rb are derepressed, leading to an apoptotic 
response.  Taken from (Delston et al., 2010) 
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